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Abstract 
The preference for a glycolytic metabolism as mean of energy production, even in the 
presence of oxygen (“Warburg effect”), is a widely described phenomenon in tumors. The 
higher glycolytic rates verified in tumour cells leads to an increase in lactate production, 
which transport out of the cell, performed by monocarboxylate transporters (MCTs) with co-
transport of a proton, contributes to an increase in cell proliferation, invasion and survival, 
by causing the acidification of tumor microenvironment. Studies have been exploring the 
role of MCTs in the metabolism of tumor cells, however the role of MCTs is controversial 
and poorly explored prostate cancer.  
The aim of this work was to understand the role of MCTs on prostate cancer cells 
survival and on cancer cell characteristic features of aggressiveness. To achieve our goals, 
we performed a detailed characterization of MCTs expression and other metabolic markers 
in two prostate cancer cell lines, with distinct phenotypes of aggressiveness. Furthermore, 
we studied the effects of MCT silencing on prostate cell models in what regards to cell 
survival, proliferation, migration and cellular energetic metabolism. Our study showed that, 
not only MCTs are expressed on prostate tumor cells, but also its silencing affects cell 
growth and metabolism, as well as proliferation and migration capacity in in vitro models. 
Importantly, there was an effective reduction of tumor growth in vivo, when MCTs were 
silenced. 
Although further studies are needed, our results demonstrate the potential of MCTs 
as therapeutic targets in prostate cancer. 
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Resumo 
A preferência por um metabolismo glicolítico pelas células tumorais como meio para 
produção de energia, mesmo na presença de condições normais de oxigénio (“efeito de 
Warburg”), é um fenómeno vastamente descrito em tumores. As altas taxas de glicólise 
verificadas nas células tumorais levam a um aumento na produção de lactato, cujo 
transporte para o exterior da célula é efetuado pelos transportadores de monocarboxilatos 
(MCTs) com co-transporte de um protão, contribuindo para um aumento na proliferação, 
invasão e sobrevivência das células, causando a acidificação do microambiente tumoral. 
Estudos têm investigado o papel dos MCTs no metabolismo das células tumorais, contudo 
esse papel é ainda controverso e pouco explorado no cancro da próstata. 
O objetivo deste trabalho foi entender o papel dos MCTs na sobrevivência e 
características de agressividade das células tumorais de próstata. Para atingir os nossos 
objetivos, realizámos uma caracterização detalhada da expressão dos MCTs e outros 
marcadores metabólicos em duas linhas celulares de cancro de próstata, com diferentes 
fenótipos de agressividade. Além disso, estudámos o efeito do silenciamento dos MCTs em 
modelos celulares de próstata no que respeita à sobrevivência, proliferação, migração e 
metabolismo energético celulares. O nosso estudo demonstrou que, não só os MCTs estão 
expressos nas células tumorais de próstata, como também que o seu silenciamento afeta 
a viabilidade e o metabolismo celulares, assim como a capacidade de proliferação e 
migração em modelos in vitro. Mais importante, houve uma redução efetiva no crescimento 
do tumor in vivo, quando os MCTs foram silenciados. 
Apesar de serem necessários estudos mais aprofundados, os nossos resultados 
demonstraram o potencial dos MCTs como alvos terapêuticos no cancro da próstata. 
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1.1. Cancer: an overview 
1.1.1. Defining cancer 
Cancer is a generic term employed to refer to a large group of diseases that can affect 
any part of the body. In a general way, the main defining feature of cancer is the rapid and 
abnormal cell growth, as well as the ability of these cells to invade other tissues and spread 
in the body through blood and lymphatic systems (i.e. metastasis), phenomenon which 
constitute the major cause of death from cancer [1]. 
More than 100 different types of cancer are known. Usually, cancers are termed in 
according to the organ or the cell type from it is originated. To simplify, cancer types can be 
grouped into broader categories, namely, carcinoma (begins in the skin or in tissues that 
cover internal organs, having several subtypes including adenocarcinoma, basal cell 
carcinoma, squamous cell carcinoma and transitional cell carcinoma), sarcoma (begins in 
bone, cartilage, fat, muscle, blood vessels or other connective or supportive tissue), 
leukemia (begins in blood-forming tissue, such as bone marrow , and causes abnormalities 
in blood cells that are produced), lymphoma and myeloma (begins in cells of the immune 
system) and central nervous system cancers (begin in the tissues of the brain and spinal 
cord) [1]. 
1.1.2. Cancer Statistics 
Worldwide, cancer is a leading cause of death with 7.6 million deaths in 2008 and 
representing around 13% of all deaths [1]. 
 
Figure 1. Worldwide incidence and mortality of cancer, in both sexes and all ages, in 2008 [1]  
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The most frequent types of cancer are, as shown in Figure 1, lung (1.6 million cases), 
breast (1.38 million cases), colorectal (1.24 million cases), stomach (1 million cases), 
prostate (900 000 cases) and liver (700 000 cases), while the most mortal is lung cancer 
(1.37 million deaths), followed by stomach and liver cancers (700 000 deaths) (see Annex I 
and II) [1]. 
Worldwide, deaths from cancer are projected to continue rising along the years, with 
an estimated 13.1 million deaths in 2030 representing, therefore, a serious threat to human 
health [1]. 
 
1.2. Prostate Cancer 
1.2.1. Disease Overview 
Prostate is a small gland that integrates the male reproductive system, with about the 
size and shape of a walnut, having a role in the production of semen (Figure 2). The prostate 
gland tends to grow with age, and, thereby, aging raises the risk of prostate problems, 
including prostate cancer [2]. 
 
Prostate cancer has a slow development compared with most other types of cancer. 
Carcinogenesis may begin until 30 years before the tumor gets big enough to cause 
symptoms or be detectable and, meantime, prostate cancer cells may eventually spread 
throughout the body and the cancer may already be advanced. In fact, a prostate tumor may 
be present for several years without causing symptoms or even become a serious threat to 
health, until the dead for some other cause [2]. 
Figure 2. Prostate context in male reproductive system [2]. 
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The main symptoms of prostate cancer are problems in the urine passageway, 
abnormal constant need to urinate, weak or interrupted urinary flow, pain or burning when 
passing urine, blood detection in the urine or semen, painful ejaculation. Importantly, 
prostate cancer can easily spread to the bones, so bone pain, especially in the back, hips 
or pelvis can be a symptom of advanced prostate cancer [2]. 
In what respect to risk factors of prostate cancer, stand out age (from 50 years-old), 
race (African-American men have the highest risk followed by Hispanic and Native American 
men, having Asian-American men the lowest rates), family history (men whose father or 
brothers had prostate cancer have a 2 to 3 times higher risk of prostate cancer and men 
who has 3 immediate family members with prostate cancer has about 10 times the risk) and 
diet (higher risk for men with a high-fat diet) [2]. 
1.2.2. The numbers of prostate cancer 
Prostate cancer is the second most frequently diagnosed cancer of men (Figure 3), 
with over 14% of total of cancers in men (914 000 new cases) and the fifth most common 
cancer overall (Figure 1) [3]. 
 
 
 
 
Figure 3. Worldwide incidence and mortality of prostate cancer in men, all ages, in 2008 [1]. 
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Incidence rates of prostate cancer vary largely around the world, being the highest 
rates located in developed countries, like Australia/New Zealand (104.2 per 100,000), 
Western and Northern Europe and Northern America (Figure 4), largely because the 
practice of prostate specific antigen (PSA) testing and subsequent biopsy that has become 
widespread in those regions. Incidence rates are relatively high in certain developing regions 
such as the Caribbean, South America and sub-Saharan Africa, being the lowest incidence 
rates in South-Central Asia [3]. 
 
As said before, prostate tumors have a slow development, being tightly related with 
the age (Figure 5) [1]. In fact, the increase in the incidence of this tumoral type in developed 
countries is tightly related with the increase in life expectancy, as well as with the diagnostic 
methods. The early diagnostic of prostate cancer possible by the prostate-specific antigen 
(PSA) test and the consequent successful treatment, may contribute to the observed gap 
between the rates of incidence and mortality rates. 
 
Figure 5. Incidence and mortality rates for prostate cancer according with the age [1]. 
Figure 4. Worldwide incidence of prostate cancer in man, all ages, in 2008 [1]. 
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1.2.3. Screening, staging and available therapies 
Screening of prostate cancer is done by standard exams, being the most often used 
tests, after the assessment of health history and symptoms, the digital rectal exam (DRE) 
and the PSA test. DRE is a palpation test which permits the assessing of several 
characteristics such as size, firmness, and texture of the prostate, as well as the presence 
of hard areas, lumps, or growth spreading beyond the prostate. Pain caused by touching or 
pressing the prostate can also be detected. The main disadvantage is that DRE only permits 
the assessment of one side of prostate, not providing a global analysis of the prostate. PSA 
test is a U.S. Food and Drug Administration (FDA) approved test that, used along with DRE, 
permits the checking of prostate’s health, enabling the detection of a prostate cancer. In a 
general way, PSA is a protein produced by prostate cells that is normally secreted by 
prostate, helping on semen production, and can move to the bloodstream. In case of 
prostate cancer, more PSA gets into the blood than is normal (>4.0 ng/mL), being a putative 
signal of the existence of a cancer. However, PSA test is not 100% reliable, since it can 
origin false-positive results, many times due to non-cancerous prostates disturbs, like 
prostatitis, as well as events that disturb the prostate gland like a simple bicycle riding, a 
prostate biopsy or surgery or even a DRE, that can increase the levels of PSA. Moreover, 
some prostate glands can naturally produce more PSA than others, according to the race 
(African-American men tend to have higher PSA levels than men of other races) and even 
some drugs can cause augment of the levels in the serum. For this, PSA test has to be used 
along with other methods of screening. This test is also often used in the follow-up of 
prostate cancer patients for the assessment of cancer recurrence [2]. 
At time of diagnosis, the extent of a cancer is a key factor to define the treatment and 
to assess the prognosis of the patients. The most widely used staging system among 
clinicians is the tumor-node-metastasis (TNM) cancer staging system (see Annex III), 
maintained and updated periodically by the American Joint Committee on Cancer (AJCC) 
and the International Union for Cancer Control (UICC), approaching important 
characteristics of the tumor: extent of the primary tumor (T), regional lymph nodes (N) and 
distant metastasis (M) [4]. Another prostate cancer classification system, widely used in 
North America, is the Whitmore-Jewett [5], also called ABCD rating or Jewett staging system 
(see Annex IV) having, however, a gap in the classification of nonpalpable tumors, detected 
by elevated PSA levels and consequent biopsy, not having a logical stage for these tumors, 
unlike the TNM system [6]. In this system, “A” and “B” refers to a localized prostate cancer, 
“C” refers to cancer growing outside the prostate but without spreading to lymph nodes or 
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other parts of the body and “D” refers to a metastatic cancer [2]. However, the most 
commonly used system for staging of prostate cancer is the Gleason Grading System 
(Figure 6) that, incorporated with other strategies, can predict the prognosis and help on 
therapy guiding. This grading system was proposed, in 1966, by Donald Gleason and is 
based on the architectural pattern of the tumor [7]. This system consisting in the sum of the 
two most common (up to 5% of the extent of the biopsy) patterns found in the tumor, giving 
a grade from 1 to 5 to each selected pattern, resulting in a score between 2 and 10, where 
2 is the less aggressive and 10 is the most aggressive. [8].  
 
The prostate cancer treatment is dependent on cancer stage, and it is not possible to 
state that one therapy is clearly better than another, however, based on the randomized 
controlled trials and on the available literature, there are some recommendations on the 
most indicated and more probably successful therapeutic approach [8]. Currently, radical 
prostatectomy (RP) is the only effective treatment for localized prostate cancer, showing a 
cancer-specific survival benefit when compared to conservative management [9], being the 
need of pelvic lymphadenectomy controversial because of the low-risk of lymph node 
involvement in men. Neoadjuvant androgen deprivation, before RP, and adjuvant androgen 
deprivation, following RP, are controversial as the advantage on free-survival of patients is 
not consistent [10]. Localized prostate cancer, as well as positive surgical margins, can be 
treated also with radiotherapy or transperineal brachytherapy, consisting in safe and efficient 
techniques [11-15]. Alternatively, patients with localized prostate cancer who are not suitable 
for RP, can be treated by cryosurgical ablation of the prostate and high-intensity focused 
ultrasound [16]. Hormonal therapy, namely either complete or intermittent androgen 
blockade, can be also an efficient approach with proven advantage on overall survival of 
patients [17-19]. Chemotherapy is not a standard treatment for early prostate cancer but is 
Figure 6. Schematic diagram of modified Gleason Score grading system, from  the 2005 International Society of Urological 
Pathology Consensus Conference on Gleason Grading of prostatic carcinoma [7]. 
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used metastatic cancers when hormone therapy is not effective [20,21]. Broad-band 
chemotherapeutic drugs, mainly docetaxel (the only FDA-approved), are used as last resort 
for this fatal stage of prostate cancer, which patients have a median survive of less than two 
years. However, tumors tends to develop resistance to taxanes [22,23]. 
 Given the current landscape of available therapies against prostate cancer, as well 
as the invasiveness of most of them, it emerges the urgency of alternative and effective new 
therapies that can fill this lack. 
 1.3. The emergence of cancer: from normal cells to tumour  
The information that allows us to understand the pathogenesis of cancer has been 
increasing along the years. In order to understand cancer biology it is essential to know the 
functional capabilities acquired by the different tumor types, during tumorigenesis [24,25]. 
Nowadays, it is now clear that cancer cells have distinctive and complementary capabilities 
giving to tumor the unlimited proliferation potential, self-sufficiency in growth signals, and 
resistance to antiproliferative and apoptotic stimuli [25]. Tumors are more than a mass of 
cancer cells, being complex tissues composed by different interacting cell types and a very 
special microenvironment, which is very important for carcinogenesis and contributes to the 
development of certain hallmark capabilities [24].  
Some years ago, Hanahan and Weinberg [26] proposed the six hallmarks of cancer 
(Figure 7) that collectively define tumorigenesis: limitless replicative potential, self-
sufficiency in proliferative signals, insensitivity to growth suppressors, evasion to cell death, 
sustained angiogenesis and activated invasion and metastasis capacity [24,26,27].  
 
Figure 7. The six hallmarks of cancer [24] 
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In recent years, an increasing body of research suggested two emerging hallmarks of 
cancer: reprogramming of energy metabolism, consisting in a capability of cancer cells to 
reprogram cellular metabolism to support neoplastic proliferation in a most effective way, 
and evading immune system effects, having cancer cells the ability to evade immunological 
destruction, in particular by T and B lymphocytes, macrophages, and natural killer cells. At 
the same time, two important cancer enabling characteristics were proposed, namely the 
heritable molecular changes (genetic and epigenetic), that can allow hallmark capabilities, 
and the tumor-associated inflammation, consisting in the promotion of tumor progression by 
immune system (Figure 8) [24]. Recognition of these concepts is crucial to the development 
of new therapeutic approaches and agents that can kill tumor cells while sparing normal 
cells [28]. 
 
 
1.3.1. Metabolic Reprogramming: an emerging feature of cancer 
The high coordination of cellular metabolism enables the cooperation of various 
metabolic pathways in the conversion of nutrient molecules into other macromolecules 
which are required for specialized functions and to obtain chemical energy for several vital 
processes. In fact, cell proliferation is required for embryogenesis, growth and some 
functions of mammals’ tissues. Differentiated tissues have basal rates of glycolysis, 
converting glucose to pyruvate, which is then oxidized in the tricarboxylic acid (TCA) cycle, 
obtaining most of the ATP (adenosine triphosphate) by a process termed as respiration  or 
oxidative phosphorylation [29,30]. Proliferating cells can induce signals that leads to a 
reorganization of metabolic activity and, so, the metabolism of proliferating cells, in contrast 
Figure 8. Emerging hallmarks of cancer, enabling characteristics and possible targeting therapy approach aiming the 
altered energetic metabolism of cancer cells (adapted from [24]).  
Aerobic Glycolysis 
Inhibitors 
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to quiescent cell, is characterized by high rates of glycolysis, lactate production, and 
biosynthesis of lipids and other macromolecules [29].  
As can be seen by observing Figure 9 [31], in the presence of oxygen, nonproliferative 
tissues metabolize glucose to pyruvate, completely oxidize most of this pyruvate to CO2 in 
the mitochondria for the process of oxidative phosphorylation, being the oxygen essential in 
this process as it is needed as the final electron acceptor, yielding 38 moles of ATP per 
molecule of glucose consumed. When oxygen is limited, cells redirect pyruvate to produce 
lactate, in a process called anaerobic glycolysis. This lactate production during anaerobic 
glycolysis allows the continuing of glycolysis, but is much less productive in terms of energy 
when compared with oxidative phosphorylation, only 2 moles of ATP per glucose molecule. 
Normal cells return to normal use of the oxidative phosphorylation when oxygen levels are 
restored, but in contrast, proliferative tissues and tumor cells continue to use glycolysis even 
in the presence of sufficient amounts of oxygen (i.e. normoxia), phenomenon known as 
‘aerobic glycolysis’ or ‘Warburg effect’, an overt manifestation of modification of the tumor 
cells metabolism. At the same time, in the mitochondria, low rates of oxidative 
phosphorylation still occur in both cancer cells and proliferating normal cells. The evident 
lower energy efficiency of aerobic glycolysis, compared with oxidative phosphorylation, 
leads the tumor cells to largely increase the rates of glycolysis in order to achieve the 
required levels of ATP, maintaining the high proliferative rates and consequently leading the 
production of large quantities of lactate [31]. 
 
Originally, Warburg described that, as result of an irreversible damage to the 
respiratory chain (oxidative phosphorylation), increased glycolysis is one way to 
Figure 9. Schematic representation of the differences between oxidative phosphorylation, anaerobic glycolysis and aerobic 
glycolysis or Warburg effect [30] 
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compensate for the failed ordinary energy-producing energy. [32] Currently, it is known that 
the metabolic changes that occur during carcinogenesis results from genetic modifications 
that may include activation of proto-oncogenes and inactivation of tumor suppressor genes 
[31]. However, although Warburg’s original hypothesis has proven incorrect, the original 
observation of increased glycolysis in tumors has been repeatedly confirmed and the 
increasing on glucose uptake has, in fact, proved useful for tumour detection and monitoring. 
18F-fluorodeoxyglucose positron emission tomography (FdG-PET) image technique (Figure 
10) has as basis the hyperglycolytic phenotype of cancer and has been largely used in 
clinical context for diagnosis, staging, prediction and monitoring of treatment response and 
surveillance of patients from various types of cancers [33,34]. The main principle of this 
technique relies on the activity of glucose transporters that are responsible for the uptake of 
the glucose analogue 2-(18F)-fluoro-2-deoxy-D-glucose (FDG), which after 
phosphorylation, is no further metabolized and becomes trapped in the cells. Accumulation 
of the radioactive glucose analogue is then detected by PET, allowing to detect tumours in 
the body [35,36]. 
 
Although the glycolytic phenotype is less efficient compared to oxidative 
phosphorylation, it is the quickest way of ATP production, suggesting that cancer cells have 
increased metabolic autonomy [31,37,38]. Tumour cells also can divert intermediates of the 
glycolytic pathway to anabolic reactions, allowing the biosynthesis of lipids, amino acids and 
also nucleotides [31,38-41]. Importantly, the Warburg effect induces a decrease in reactive 
oxygen species (ROS) production, protecting cells from oxidative stress. Additionally, the 
Figure 10. PET imaging with FDG of a patient with lymphoma. The nodes represented by purple and green arrows show a 
high uptake of FDG, showing that tumors in these nodes have high levels of FDG uptake. The bladder (yellow arrow) also has 
a high activity, because of excretion of the radionuclide [31]. 
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greater production of lactic acid (lactate), which contributes to acidic microenvironment, 
confers advantages to tumour cell growth and proliferation, increasing several malignant 
features like migration, invasion and metastisation [37,38]. 
During carcinogenesis, aerobic glycolysis can cooperate with mitochondria during 
cancer progression, evidencing the metabolic plasticity of cancer cells [41-44]. In fact, recent 
studies demonstrate a directly link between Warburg effect and mitochondrial defects, as 
well as to oncogenic activation and mutation in signaling pathways that regulate glucose 
uptake, such as PI3K/Akt/mTOR pathway [37,40]. Additionally, selection of the glycolytic 
phenotype in tumour cells can be mediated by the action of transcription factors [34,38,45], 
like the hypoxia-inducible factor 1-alpha (HIF-1α) [45], MYC [45], Ras and p53 [46]. 
Thus, a nearly universal property of cancer, both primary and metastatic, is increased 
glycolysis, resulting in increased consumption of glucose leading, consequently, to a 
hyperglycolytic phenotype. This hyperglycolytic phenotype leads to microenvironmental 
acidification requiring changes in cell phenotype in order to resist to acid-induced cell 
toxicity. The following cell populations with increased glycolysis and acid resistance, have a 
powerful growth advantage, which promotes a free proliferation and invasion [31]. 
1.3.2. Tumoral microenvironment: acidic and hypoxic  
The avascular environment where carcinogenesis have risen, presupposes a 
dependence, by cancer cells, on glucose and oxygen diffusion, through blood vessels and 
basement membrane, in order to achieve their major metabolic needs [31] and, in fact, early 
carcinogenesis cannot occur more than a few cell layers far from the basement membrane 
or regional hypoxia would limit cell growth. Thus, tumor cells have to perform several 
adaptations on their metabolism, like rapid ATP production, increased biosynthesis of 
macromolecules and maintenance of adequate cellular redox status [47], facing the stressful 
and dynamic microenvironment of solid tumors, where concentrations of some nutrients like 
glucose, glutamine and even oxygen are spatially and temporally heterogeneous [48]. 
Moreover, the intermittent hypoxia conditions observed in tumor microenvironment leads to 
a Darwinian-like selective pressure on cancer cells, contributing to the constitutive up-
regulation of glycolytic phenotype observed in most tumors [31,37,47,49]. Additionally, 
characteristics of tumors like the abnormal vasculature and the altered pH can influence 
tumour microenvironment, contributing also to the glycolytic phenotype [50].  
Then, the tumour cell population that emerges from the referred evolutionary 
sequence, acquiring a constitutive glycolytic phenotype by selective pressure of hypoxia, 
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has a powerful proliferative advantage, being able to alter their environment in a way that is 
harmless to itself, but toxic to other cellular phenotypes. The environmental acidosis, 
through increased concentration of lactate, contributes to the invasive phenotype through 
degradation of the extracellular matrix and promotion of angiogenesis (Figure 11) [31]. 
  
 
1.3.2.1. Hypoxia: a “only for a few” favorable environment 
Hypoxia is a common microenvironmental feature of malignancy in solid tumors. 
Altogether, several factors contribute to deficient oxygen supply (i. e. hypoxia)  in tumor 
cells, namely the inability to keep angiogenesis with tumour growth, the presence of 
disorganized and abnormal vasculature within the tumour and also the increased hydrostatic 
pressure within the tumour leading to microvasculature compression [41]. As response to 
an adverse environment, tumour cells do not induce cell death but otherwise initiate 
response mechanisms that favors cell survival and migration, namely activation of the 
transcriptional factor HIF-1α, a widely known regulator of hypoxic stress, which has been 
widely associated with cancer progression [51-56]. This transcription factor is a heterodimer 
composed of an oxygen dependent α subunit and a constitutively expressed non-oxygen 
dependent β subunit. HIF-1 α subunit is degraded in the presence of oxygen (> 5% O2) but 
otherwise is stabilized under hypoxic conditions (< 5%O2) and translocated to the nucleus 
Figure 11. Model for cell-environment interactions in carcinogenesis [31]. Cell colours represent different cell types: grey for 
normal epithelial cells, pink for hyper-proliferative cells, blue for hypoxic cells, green for glycolytic cells and yellow for motile 
cells. Light orange nuclei represent one mutation while dark orange nuclei represent more than one mutation. Blebbing 
membranes show apoptotic cells. Abbreviations: HIF-1α, hypoxiainducible factor 1 alpha; VEGF, vascular endothelial growth 
factor. 
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forming a HIF-α/β complex which can bind to target genes on their hypoxic-response 
elements (HREs) [57,58]. The binding of HIF-α/β to HREs results in transcriptional up-
regulation of target genes that mediate multiple adaptations that leads to resistance to 
hypoxia, namely enzymes involved in the glycolytic pathway, as well as the vascular 
endothelial growth factor (VEGF) that promotes angiogenesis (Figure 12) [59]. 
 
 
 
In fact, as one may think, the up-regulation of HIF-1α in various types of solid tumors 
is associated with poor clinical outcome [59]. Importantly, HIF-1α activation is effective, not 
only in stimulating glycolysis, but also in decreasing oxidative phosphorylation, which allows 
to equilibrate O2 consumption with the poor O2 supply [60]. In a general way, HIF-1α can 
compromise oxygen consumption in oxidative phosphorylation by induction of pyruvate 
dehydrogenase kinase-1 (PDK1) expression, which inhibits the mitochondrial pyruvate 
dehydrogenase (PDH), preventing conversion of pyruvate into acetyl-CoA and consequently 
its diversion to the respiratory pathway (Figure 13). One more time, as consequence of 
global oxidative phosphorylation reduction, hypoxic tumour cells are forced to increase the 
glycolytic metabolism in order to maintain the production of ATP for cell survival. Therefore, 
HIF-1α regulates the expression of glucose transporters (GLUT-1 and GLUT-3) to increase 
glucose uptake and also induces the expression of several downstream glycolytic, such as 
hexokinase II (HK2) and pyruvate kinase type 2 (PKM2). The metabolic reprogramming 
mediated by HIF-1α redirects pyruvate to another HIF-1α target, lactate dehydrogenase 
(LDH-A) that catalyzes the conversion of pyruvate to lactate [58,60-62]. The increase in 
PDK1 
Figure 12. Scheme representative of HIF-1α degradation under normoxia conditions, and activation by hypoxia (adapted 
from [66]). Under normoxia conditions, HIF-1α is hydroxylated, ubiquitylated and further degraded. Under hypoxia conditions, 
HIF-1α protein is expressed, migrates to the nucleus and binds to HIF-β and further to HRE in promoting regions, which 
induce glycolysis, angiogenesis, erythropoiesis and vasomotion. 
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lactic acid production amongst the diminished vascular dispersion of CO2 contributes to 
hypoxic acidosis, and therefore to the acid-resistant phenotype. In this context, other type 
of proteins, that are also targeted by HIF-1α, arises for pH regulation, namely carbonic 
anhydrase IX (CAIX), which is a hypoxic marker and a prognostic indicator which performs 
the reversible conversion of CO2 to bicarbonate and proton, contributing to extracellular 
acidification of tumour microenvironment and consequently to control of intracellular pH 
[58,63], and monocarboxylate transporters (MCTs) [57,58,61]. It is already described the 
up-regulation of MCT4 in hypoxia, where it cooperates with MCT1 in lactate efflux [58,64] 
and, for that, MCTs will have a dual role in cancer, both for the acid-resistant phenotype and 
for the hyper-glycolytic phenotype, allowing the continuous conversion of pyruvate to lactate 
by performing the lactate efflux and consequent clearance of the glycolytic pathway [65]. 
 
 
The frequency and severity of tumor hypoxia and its association with malignant 
progression make hypoxia induced metabolic changes promising therapeutic targets for 
cancer therapy [47] and, in fact, some clinical trials are already in course [66]. 
Figure 13. HIF-1 promotes the expression of glycolytic enzymes and transporters (adapted from [66]). Green arrows point at 
HIF-1 target gene products directly involved in increased glycolytic flux. Abbreviations: CAIX: carbonic anhydrase IX; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; GLUT, glucose transporter; MCT4, monocarboxylate transporter 4;PPP, 
pentose phosphate pathway; TCA, tricarboxylic acid (cycle).  
CA 
IX 
CO2 + H2O 
HCO3- + H+ 
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1.3.2.2. Lactate transport: a great contributor to malignancy  
The increase in glycolysis typical in cancer cells leads to acidification of tumour 
microenvironment, having cancer cells, as referred above, different membrane pH 
regulatory mechanisms. This include the activity of proteins, such as MCTs, CAIX, as well 
as Na+/H+ exchanger 1 (NHE1) and anion exchanger 1 (AE1), that allow the survival, 
growing and selection of cancer cells in this microenvironment which otherwise will be fatal. 
Although MCTs are not the major proton transporters in cells, its importance turns out to be 
enhanced due to their dual role in the adaptation to the microenvironment: export of lactate 
- essential to the hyper-glycolytic phenotype - and pH regulation, important to the acidic-
resistant phenotype [67]. The acidification of the extracellular space is, in a large part, 
mediated by MCTs, specifically MCT1 and MCT4, due to the co-transport of lactate with 
protons [31]. It is known that microenvironmental acidity is associated with cancer cell 
invasion and migration, allowing metastasis [68,69] and that lactate contributes to several 
features of tumour progression and malignancy, like immune escape [70], angiogenesis 
[68,71], radioresistance [72] and high incidence of distant metastasis [73], highlighting its 
active role, and therefore the role of MCTs, in progression of malignant diseases (Figure 14) 
[69,73].  
Lactate produced by glycolytic tumour cells is largely associated with poor prognosis, 
disease-free and overall survival in several cancers like cervical cancer [74], head and neck 
cancer [75], high grade gliomas [76], non-small-cell lung metastasis [73] and prostate [77], 
as well as with radioresistance in some tumors caused, in part, by the antioxidant properties 
of lactate [69]. Additionally, evidence shows that, independently from the oxygen conditions,  
lactate can regulate hypoxia inducible genes by stimulating the accumulation of HIF-1α [78], 
which would lead, in turn, to a stimulation of the glycolytic pathway by regulating glycolytic 
enzymes as already referred, providing an important positive feedback in the context of 
cancer. Moreover, lactate was demonstrated to increase cellular motility [79], VEGF  [80], 
as well as molecules involved in the process of cancer invasion and metastisation, namely 
hyaluronan and its receptor CD44 [81,82] and even the expression of proteins associated 
with increased migration capacity of cancer cells, namely transforming growth factor (TGF-
β2) [83]. Importantly, besides the glycolysis, there are other pathways that, in a lower extent, 
can contribute to lactate production in solid tumors, such as glutaminolysis and serinolysis 
(Figure 14) [84,85]. 
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However, lactate properties that contribute to malignancy do not stop here. Besides 
its referred roles in acidification, mutation, promotion of invasive behavior and factor in 
radioresistance of cancer cells [31], lactate has another important role, not least important, 
in the tumoral aggressiveness context, namely on the T-cell activation, which is dependent 
on high rates of glycolysis and on the rapid efflux of lactate from T cells [86], but stay 
compromised if the extracellular concentrations of lactate are sufficiently high leading to a 
negative feedback that blocks its efflux and thus disturbs the metabolism and function of T 
cells, consequently decreasing the immune response against tumour cells [70].  
Moreover, besides being mainly an end-product, lactate exported from a cell may also 
be a substrate for neighbor cells, as described in skeletal muscle and brain [87-89], 
phenomenon currently known as the “cell-cell lactate shuttle”, in which the peripheral and 
oxygenated oxidative cells consume the lactate produced by the central and hypoxic 
glycolytic cells (Figure 15). Additionally, intracellular lactate has been also described as a 
key metabolic intermediate in a symbiosis between glycolytic and oxidative cancer cells, by 
entering the mitochondria via MCTs [65,90]. 
Figure 14. Overview on the metabolic pathways leading to lactate production (continuous lines) and transport across the 
plasma membrane (adapted from [67]. Discontinuous arrows represent lactate uptake and flow inside oxidative cancer cells. 
Abbreviations: LDH, lactate dehydrogenase; MCT, monocarboxylate transporter; PDH, pyruvate dehydrogenase; PDK1, 
pyruvate dehydrogenase kinase 1. 
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Figure 15. Intratumoral hypoxia and metabolic symbiosis. LDHA/B, lactate dehydrogenase A/B; PDK1, pyruvate 
dehydrogenase kinase1; MCT1/4, monocarboxylate transporters 1/ 4; CAIX, carbonic anhydrase IX; NHE1, Sodium-Hydrogen 
Exchanger1; HIF-1α, hypoxia-inducible factor (adapted from [90]). 
 
Altogether, these characteristics and roles allow lactate to be seen as a suitable 
candidate for diagnostic and prognostic indicator for a wide variety of tumors, being 
reasonable to think that targeting of its transport may be a promising approach for cancer 
therapy [68]. 
 
1.4. Monocarboxylate Transporters 
Monocarboxylic acids, such as lactate and pyruvate, play a key role in cellular 
metabolism and in inter-tissue communication. [91] The rapid transport of these compounds 
across the plasma membrane is essential for this role, being mediated by the 
monocarboxylate transporters (MCTs), as shown in Figure 16 [91]. 
The presence of MCTs is vital in tissues which energy supply relies on glycolysis and 
therefore depends on the intracellular lactate transport across the plasma membrane to 
maintain the high glycolytic rates, such as white skeletal muscle, red blood cells and tumour 
cells. Additionally, tissues like brain, heart and red skeletal muscle, without forgetting 
gluconeogenic tissues, like kidney and liver tissues, where lactate could be the major source 
of energy, being oxidized as a respiratory fuel, are also dependent on MCTs’ activity in the 
uptake of lactate into the cells [91]. 
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In fact, MCTs have a central role in mammalian cellular metabolism as well as in the 
communication between cells since they catalyze the lactate facilitated transport across the 
plasma membrane in a proton symport way, being upregulated in cancer cells, which have 
increased glycolysis. [91] Although lactate is the main monocarboxylic acid transported by 
MCTs, there are also other metabolically important monocarboxylates transported such as 
pyruvate, branched-chain oxo-acids derived from leucine, valine and isoleucine, 
acetoacetate, β-hydroxybutyrate and ethyl acetate [91]. The bet in the characterization of 
monocarboxylate transport in different cell types like erythrocytes, cardiac myocytes and 
hepatocytes, among others, led to the hypothesis of the existence of a MCT family [92]. 
 
1.4.1. The MCT family 
The Solute Carrier Family 16 (SLC16), or MCT family, is encoded by the SLC16 
genes, showing conservation among species including mouse, rat and chicken [93]. 
Phylogenetic studies allowed the identification of the 14 known members of MCT family 
(SLC16 genes), and provided important information about the functional clustering of the 
human MCT family [67]. Figure 17 shows that MCT1-MCT4 are associated in the same 
cluster, presenting a high homology and, in fact, after functional characterization, only 
MCT1-MCT4 have demonstrated the proton-linked transport of monocarboxylic acids [67]. 
Figure 16. Diagram of the metabolic pathways involving the monocarboxylate transporter through the plasma membrane and 
mitochondria [91]. Abbreviations: Glc-1-P and Glc-6-P, glucose 1-phosphate and glucose 6-phosphate; Ac-bHB, acetoacetate 
plus b-hydroxybutyrate. 
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Importantly, this cluster is yet sub-divided into two branches, MCT1-2 and MCT3-4, which 
correlate with the transported substrate as well as the affinities by which those transport is 
performed [94-101]. 
The topological prediction of MCTs show a structure of 12 transmembrane domain 
(TMD) helices with both intracellular amino and carboxyl terminal, presenting a large loop 
between TMDs 6 and 7 and having a range of 29-105 amino acid residues [102]. These 
transmembrane regions are the most conserved [103], in contrast to the hydrophilic regions, 
which show little conservation avoiding those regions to be the responsible for the transport 
and possibly pointing their role to functional aspects such as substrate specificity or 
regulation of activity [104].  
 
 
Topological prediction for MCT1 was experimentally confirmed in erythrocytes (Figure 
18) [105] but a similar topology could be predicted for other isoforms based on aminoacidic 
sequence analysis [93]. In what regards proton coupling, typical from MCTs, the N-terminal 
domain of the MCT protein is pointed to be the main responsible, being also associated with 
the membrane insertion and the maintenance of the structure. On the other hand, C-terminal 
domain is pointed to be important for substrate affinity [91]. The ability of MCTs to transport 
monocarboxylates, along with a proton, across the plasma membrane lead to the 
reasonable prediction that TMD’s amino acids are more likely responsible for proton binding 
Figure 17. Human MCT family members’ phylogram, based on amino acid sequence. Boxes limited by dots represent three main 
clusters. In the doted-dashed box are the thyroid hormone (MCT8) and aromatic amino acids (MCT10) transporters. Solid grey 
box represent the proton-linked transported cluster (MCT1-4) [67]. 
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and translocation being the only conserved aspartate/glutamate residue in the N-terminal 
already described as a candidate [91,93,106]. In fact, studies of site-directed mutagenesis 
in highly conserved residues of MCTs, confirmed the role of TMDs on lactate transport 
carried out by this protein [91,103]. Additionally, the presence of asparagine’s in extracellular 
loops of the transporter would denote possible sites for glycosylation, a common 
phenomenon for membrane spanning proteins, despite the theoretical predictions and 
experimental evidence indicates absence of glycosylation in MCTs [107]. 
 
                Figure 18. MCT1 protein diagram [105]. 
 
1.4.1.1. MCT isoforms 
The main differences between the various MCTs isoforms are related to substrate and 
inhibitor affinities, the regulation of their expression, and their tissue distribution and 
intracellular localization [108]. Here, it will be focus mainly on MCT1, MCT2 and MCT4 
isoforms, whose function is responsible for the name of the family of transporters and more 
relevant in cancer.  
1.4.1.1.1. MCT1 
SLC16A1, the human MCT1 gene (NCBI Reference Sequence: NP_001159968.1), 
was cloned by Garcia and colleagues in 1994, in Chinese hamster ovary cells (CHO) [109] 
and subsequently, by others, in human, rat and mouse [102], constituting the most studied 
MCT isoform, due to both its unique expression in human erythrocytes and its ubiquitous 
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tissue distribution [107]. Although it was already known that SLC16A1 was located in 
chromosome 1, the structural gene characterization of SLC16A1 promoter was only 
achieved in 2002 [110] bringing these results the information that the transcription of MCT1 
have a universal promoter, which is consistent with its broad tissue distribution [107]. As 
functional protein, MCT1 is composed by 494 amino acids, having a molecular weight of 
~54 kDa [106]. 
As already referred, MCT1 is present in several and different cells and tissues, such 
as in blood-brain barrier (BBB), T-lymphocytes, spermatogenic cells, brain, apical 
membrane of retina pigmented epithelium (RPE), inner ear, kidney, stomach, liver, gut 
epithelium, among others, where it is required for membrane transport of monocarboxylates 
[107]. Additionally, MCT1 has been described to be expressed in mitochondria [111] and 
peroxisomes [112] where it seems to participate in a lactate oxidation complex to maintain 
organelle redox status.  
In what regards the transport activity, MCT1 exhibits an intermediate substrate affinity, 
allowing it to perform both the uptake and efflux of monocarboxylates from cells, which may 
constituting an explanation for its wide pattern of expression [67]. Importantly, MCT1 is 
capable to transport a large variety of substrates, including short chain (C2-C5) unbranched 
aliphatic monocarboxylates such as acetate and propionate, as well as monocarboxylates 
with C2 or C3 substitutions, as pyruvate, L-lactate, β-hydroxybutyrate and acetoacetate and 
more poorly, formate and D-lactate [67,91,93,103,107]. Bicarbonate, dicarboxylates, 
tricarboxylates and sulphonates cannot be transported [93] and may even act as potent 
competitive inhibitors of the transport of other monocarboxylates [103].  
Importantly, the MCT1 optimal plasma membrane expression and function on export 
or uptake of monocarboxylates requires a chaperone, CD147 (described later), as shown in 
Figure 19 [93].  
 
 
             Figure 19. Membrane topology proposed for MCT1 and CD147 [93]. 
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1.4.1.1.2. MCT2 
SLC16A7, firstly cloned and sequenced from a hamster liver cDNA library by Golstein 
and Brown’s group and, more recently, characterized in Xenopus oocytes, has already been 
cloned and sequenced from rat, mouse and human, being located in chromosome 12, 
containing 484 amino acids and having a molecular weight of ~52kDa [91].  
The properties of MCT2 (NCBI Reference Sequence: NP_004722.2) are not well 
understood in comparison with other isoforms of MCTs. MCT2 shows limited distribution, in 
contrast to MCT1, existing evidences for alternative spliced mRNA species in human and 
rat [104,113]. This isoform shares with MCT1 about 60% of its sequence however, several 
analyses have been shown that MCT2 has a much more restricted tissue distribution and 
expression level when compared to MCT1 [91,93,106-108]. High levels of MCT2 expression 
was found in human testis and colon [102,107] and moderate to low levels in spleen, heart, 
kidney, pancreas, skeletal muscle, brain, and leukocyte [107]. In tissues expressing both 
MCT2 and MCT1, the expression differs in location, suggesting distinct functional roles 
between these isoforms which may be related to high substrate affinity verified for MCT2 
[103], in contrast to MCT1. Importantly, MCT2 also catalyzes the proton-linked transport of 
a variety of monocarboxylates, however, a preference was demonstrated for both pyruvate 
transport and L-lactate [106,107] in human MCT2 expressed in Xenopus oocytes [107], as 
well as for ketone bodies and β- hydroxybutyrate [106]. Therefore, MCT2 appears as a high 
affinity transporter, performing preferentially the uptake of monocarboxylates into the cells 
in normal cell metabolism [99], being consequently found in tissues that use lactate as a 
respiratory fuel, like brain or cardiac and skeletal muscle, as well as gluconeogenic tissues 
where lactate is the major substrate, like kidney and liver [104]. Additionally, as well as 
MCT1, MCT2 is also found in mitochondria  [114]. For its optimal membrane expression and 
function, MCT2 needs also a chaperone, called gp-70 or EMBIGIN [113]. 
 
1.4.1.1.3. MCT4 
MCT4 isoform (NCBI Reference Sequence: NP_001035887.1), encoded by SLC16A3 
gene, was initially called MCT3 based on its sequence homology with the MCT3 described 
in chicken, identified by Price and colleagues. Lately, when a distinct MCT3 was identified 
in mammalian retinal pigment epithelium (RPE), the name was modified for MCT4 [91,103]. 
The human MCT4, is located in chromosome 17, being constituted by 465 amino acids and 
corresponding to a molecular weight of ~50kDa.  
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In opposition to MCT2, and as well as MCT1, MCT4 has a wide distribution, being 
described its particular strong expression, and therefore having particular importance, in 
glycolytic tissues which need to export lactate, such as white skeletal muscle fibers, 
astrocytes, white blood cells and chondrocytes and, as it could not fail to be, in tumors 
[93,103,108]. Consistently, MCT4 appears in exclusively neonatal heart, which is more 
glycolytic than adult heart as well as in placenta, being involved in the transference of lactate 
into the maternal circulation [93]. Altogether, this facts indicates that the main activity of 
MCT4 may be the lactate efflux derived from glycolysis [103] which is consistent with its 
kinetic properties [100], which shows a lower affinity for L-lactate and pyruvate than MCT1 
and MCT2 [93,102,103,107]. Such as MCT1, MCT4 requires CD147 as a chaperone [91]. 
 
1.4.1.1.4. Other MCT isoforms 
Besides MCT1 (SLC16A1), MCT2 (SLC16A7)  and MCT4 (SLC16A3), there are other 
isoforms of MCTs associated with different anatomical features, which have been 
characterized along the years [91]. Firstly, MCT3 is preferentially expressed in the base-
lateral membrane of the RPE and has a role in regulation of pH and lactate concentrations 
in the outer retina [106,107,115], choroid plexus [106,107] and brain [116]. MCT6 
(SLC16A5) is a bumetanide transporter, which carriage is very sensitive to pH and 
membrane potential, without dependence on the proton gradient [93,117]. MCT8 (SLC16A2) 
is described as a thyroid hormone transporter [118], recently in parallel with SLC18A10 gene 
which also encodes for an aromatic amino-acid transporter (T-type amino-acid transporter 
1), being known as TAT1 more than MCT10 [91,103]. SLC16A2 is a thyroid hormone 
transporter and mutations in this gene have been associated with X linked severe mental 
retardation and neurological dysfunction [103]. MCT12 (SLC16A12) has the known function 
of setting/maintaining homeostasis in the cells of the eye and kidney [119] and, although its 
substrate is still unknown, is already described that mutations in this gene are associated 
with development of cataracts [93]. Importantly, SLC16A12 has been identified as a possible 
biomarker for colon, prostate and breast carcinoma, due to gene hypermethylation [120]. 
MCT9 is associated with changes in uric acid [93,121], however its specific action and 
substrate remains unknown, like for other members of the family (MCT5, MCT7, MCT11, 
and MCT13 MCT14). 
 
 
 
Chapter 1  General Introduction 
54 
1.4.2. MCT regulation by chaperones 
As previously mentioned, functional expression of MCTs depends on a type of 
accessory proteins for their trafficking and anchoring to the plasma membrane, called 
chaperones, since MCTs are not glycosylated, a common characteristic of membrane 
proteins [67,91,93,106,107].  Presently, the described chaperones for MCT1 and MCT4, 
major glycolysis-associated carriers, and therefore with the greater relevance in cancer, are 
both CD147 and CD44. 
CD147, also known as basigin (BSG), EMMPRIN (Extracellular matrix 
metalloproteinase inducer), OX-47 or HT7, is a membrane glycoprotein widely distributed in 
the plasma membrane and belongs to the immunoglobulin superfamily (Ig) [122]. One of the 
main functions of CD147 is to induce the production of matrix metalloproteinases that 
degrade extracellular matrix, promoting invasion and metastasis of tumor cells [122]. 
Specifically interacts with MCT1, MCT3 and MCT4, but not with MCT2, playing an essential 
role in their functions [123] and therefore it becomes important in the metabolism of tumor 
cells of several cancers [123-131]. Moreover, the co-expression of CD147 with MCT1 is 
associated with poor prognostic features, supporting the action of CD147 as chaperone and 
matrix metalloproteinase inducer, as observed in breast and gastric carcinoma [128,130]. 
Besides the role of CD147 as chaperone for MCT1 and MCT4 plasma membrane trafficking 
and activity, these MCT isoforms have, in turn, implications in CD147 membrane expression 
[124,125], so the contribution of MCTs to the malignant phenotype is not only at the level of 
its function on lactate transport and pH regulators, but also in their role on regulation of 
CD147 expression, which can enhance several malignant behaviors of cancer cells, like 
migration and invasion [132-135]. Therefore, targeting CD147, which also impair MCT 
activity, appears to be a rational therapeutic approach against human cancer, as already 
described both in vitro and in vivo [136-138]. 
CD44, in turn, is a multistructural and multifunctional cell surface molecule involved in 
cell proliferation, cell differentiation, cell migration, angiogenesis, presentation of cytokines, 
chemokines, and growth factors to the corresponding receptors, and docking of proteases 
at the cell membrane, as well as in signaling for cell survival. All these biological properties 
are essential to the physiological activities of normal cells, but they are also associated with 
the pathologic activities of cancer cells [139]. CD44 may also function as a chaperone for 
MCT expression [135], being described to be associated with MCT1 in lung cancer [129].  
Thus, the interaction with CD44, enhances the role of MCTs in cell growth control, adhesion, 
migration, invasion and chemo-resistance [140-142]. However, the prognostic value of this 
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protein has been shown inconsistencies as it is associated both with both poor and favorable 
prognosis, depending on the tumor type, so these doubts have to be overcome before the 
application of targeted therapies against CD44 in human cancers [139].  
Additionally, there are studies already describing an interaction of embigin, known 
MCT2 chaperone, with MCT1 in rat erythrocytes [143], however further studies are needed 
to investigate this putative interaction in the context of cancer.  
Importantly, there is a relevant number of cases with MCT plasma membrane 
expression with a lack of CD147 or CD44 co-expression, suggesting that more chaperones, 
not yet identified, may be involved in MCT function [67]. 
 
1.5. MCT expression in human solid tumors 
Recapitulating, high levels of lactate production and the consequent 
microenvironmental acidosis, is a common feature observed in tumour cells, leading to the 
assumption that MCTs, especially MCT1 and MCT4, which are the major transporters of 
lactate across plasma membrane, may have a central role in cancer [103,108]. In the last 
years, studies reported upregulation of MCTs in different human solid tumors, showing 
evidence on importance of MCTs in cancer biology. 
Evidence for MCT up-regulation was found in colorectal carcinomas [129,144-146], 
lung cancer [129,147], soft tissue sarcomas [148], cervical cancer [127,149], ovarian cancer 
[150], pancreatic cancer [136], prostate cancer [77,151], breast carcinomas [130,152], 
gastrointestinal stromal tumors (GISTs) [153], glioblastoma [154] and even melanoma [155]. 
Lambert and colleagues described, some years ago, that the transition area from normal to 
malignant phenotype of a tumor, presented a down-regulation in MCT1 expression [146], 
however, more recent studies shows evidence for the upregulation of MCTs in colon 
adenocarcinoma [129], pairing with a significant increase of MCT expression in cancer cells 
in comparison with normal cells [144,145]. This contradictions, may have arisen at the level 
of antibody specificity, which is consistent with the lack of membrane expression for MCT1 
in the first study, which would be imperative for the correct role of MCTs in lactate export 
[67]. Importantly, association of MCT expression with clinicpathological data of patients 
showed significant associations between membrane expression of MCTs and vascular 
invasion [144].  
Epithelial ovarian cancer, both primary and metastatic, shows an up-regulation of 
MCT1 and MCT4 in about 80%, compared with normal and benign ovarian tissues [150]. 
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Pinheiro and colleagues, also reported expression of MCT1, MCT2 and MCT4 in ovarian 
carcinoma, but with a lower frequency for MCT4 [129]. 
An association was found in cervical cancer between lactate production, and therefore 
the role of MCTs, and the increased incidence of metastasis and short disease free and 
overall survival [149]. Pinheiro et al. found a significant increase in MCT1 and MCT4 
expression both from pre-invasive to invasive squamous lesions and from normal glandular 
epithelium to adenocarcinomas [149]. 
In gastrointestinal stromal tumors (GISTs), MCT1, MCT2 and MCT4 are highly 
expressed, being the co-expression of MCT1 and CD147 associated with low overall 
survival of the patients [153]. 
Ependymomas, hemanglioblastomas and high grade gliomas (anaplastic 
astrocytomas and glioblastoma multiforme) show an upregulation of MCT1 in comparison 
with the general absence of its expression in low-grade glial neoplasms (oligodendrogliomas 
and astrocytomas) [154,156].  
In lung cancer, MCT1 show overexpression in the plasma membrane, in contrast with 
normal lung where there was no expression of this MCT isoform [157]. However, a study by 
Pinheiro and colleagues showed a high frequency of MCT1 expression in normal lung, being 
MCT4 less expressed in tumoral than in normal lung [129]. Additionally, a cytoplasmic 
expression of MCT1 was described in alveolar soft tissue sarcoma [148]. 
Evidence for MCT down-regulation was described in breast cancer [152]. However, a 
study of Pinheiro and colleagues demonstrated a significant increase of MCT1 either in 
cytoplasm or plasma of breast carcinoma cells, in comparison with normal breast epithelium, 
being MCT4 expression more cytoplasmic [129,130]. Importantly, MCT1 expression shows 
an association with basal-like subtype of breast cancer [130]. 
In gastric carcinoma, the results were different of those obtained for the already 
referred tumor types. In fact, MCT1 was similarly expressed in normal gastric mucosa, 
primary tumors and lymph-node metastasis, which may indicates the role of MCT1 in gastric 
homeostasis maintenance, both in normal tissue and along carcinogenesis. Moreover, 
MCT4 expression showed a significant decrease in the plasma membrane of gastric cancer 
cells [128]. 
Finally, in what regards prostate carcinoma, the available studies are controversial 
[151,158] and more studies are warranted to better elucidate the expression pattern of MCT 
in prostate tissues. The available information on MCT expression in prostate cancer will be 
developed in the next section. 
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Altogether, the available data suggests the contribution of MCTs to the hyper-glycolytic 
and acid-resistant phenotype, being the up-regulation of MCTs in the plasma membrane of 
the different types of tumors, an adaptive mechanism to allow continuous high glycolytic 
rates, by exporting the accumulating end-product, lactate, as well as to counteract the acid-
induced apoptosis or necrosis [67]. 
1.5.1. Expression of MCTs in prostate cancer 
As said in the previous section, knowledge on the role of MCTs in prostate cancer is 
somehow controversial, highlighting the need of more studies in this field.   
Hao et al., in a first approach, described MCT1 and MCT4 as being widely expressed 
in prostate cancer and unexpressed in normal prostate tissues [151]. However, Pértega-
Gomes and colleagues, showed an increase in MCT2 and MCT4 isoforms, while MCT1 
appeared to have a decreased expression in human samples of prostate cancer, when 
compared with normal tissues [158]. Importantly, MCTs showed to be expressed 
preferentially between normal and tumoral tissue in PIN lesions, suggesting the role of these 
proteins in the malignant transformation. It was also found an association between MCT1, 
MCT4 and CD147 expression and poor prognosis of the patients, being MCT4 and CD147 
overexpression correlated with higher PSA levels, Gleason Score, pT stage, perineural 
invasion and biochemical recurrence [77]. Pértega-Gomes et al. also demonstrate that, 
along with α-methylacyl-CoA racemase (AMACR), a marker already used in prostate cancer 
diagnosis [77,159], MCT2 is consistently expressed in prostate cancer, becoming a putative 
positive biomarker in prostate cancer, highly enhancing the accuracy of prostate cancer 
diagnosis [160] when used along with the two known negative markers, p63 and 34E12 
[160]. 
 
1.6. MCT inhibition: a promising weapon against cancer 
Carcinogenesis is the reflex of several genetic alterations which leads, among other 
effects, to a reorganization of metabolic pathways to support biosynthesis, allowing the cell 
autonomous nutrient uptake and therefore enhancing cell resistance to death [39,48]. This 
metabolic alterations, along with the already referred hypoxia-induced metabolic alterations, 
and its association with malignant progression constitute promising targets for cancer 
therapy [47]. In fact, the development of treatments that target tumour metabolism has been 
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a bet of research in the last years, with several potential drugs for metabolic pathways-
targeting, being already in clinical trial phase (Figure 20) [28,66,161]. 
 
Figure 20. Actual and future therapeutic targets (dashed lines) of tumour metabolism by targeting metabolic enzymes [160]. 
5-FU, 5-fluorouracil; αKG, α-ketoglutarate; ACLY, ATP citrate lyase; CA, carbonic anhydrase; CINN, α-cyano-4-
hydroxycinnamate; DCA, dichloroacetate; FASN, fatty acid synthase; G6P, glucose-6- phosphate; Glut, glucose transporter; 
HK, hexokinase; IGF1, insulin-like growth factor 1; IGF1R, IGF1 receptor; LDH, lactate dehydrogenase; Mal, malate; MCT, 
monocarboxylate transporter; NHE1, Sodium-Hydrogen Exchanger 1; OAA, oxaloacetate; PDH, pyruvate dehydrogenase; 
PDK, pyruvate dehydrogenase kinase; PEP, phosphoenol pyruvate; PK, pyruvate kinase; R5P, ribose 5-phosphate; TCA, 
tricarboxylic acid cycle. 
 
As already mentioned, the acid-resistant phenotype is essential for cancer cell 
survival, being MCTs important pH regulators that contribute to that phenotype [162]. 
Although MCTs are not the major H+ transporters, they perform a dual role in cancer 
adaptation to microenvironment: export of lactate, essential for the maintenance of the 
hyper-glycolytic phenotype, and pH regulation, important for the acid-resistant phenotype. 
Accordingly, MCT inhibition will have a direct effect on cell pH regulation and glycolytic rates, 
therefore having an important effect on cell viability [67]. Additionally, MCTs have a crucial 
role in metabolic symbiosis between cancer cells [65], so targeting these transporters will 
“shut-down” the advantageous symbiosis, likely having an important impact on tumour 
homeostasis. Finally, taking into account the contribution of lactate to the malignant 
phenotype, together with the up-regulation of MCTs in some tumors, MCT inhibition may be 
a useful therapeutic approach in cancer. This will contribute to increase the immune 
response against tumour cells and decreased its migration capacity, among others [67]. Also 
MCT inhibition, namely MCT1, offers the opportunity to simultaneously target tumour 
metabolism and angiogenesis [65,66,71]. 
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In the last years, it was demonstrated that in vitro MCT1 inhibition decreases 
intracellular pH [65,155,163], leads to cell death [65,163-165] and, importantly, enhances 
cancer cell radiosensivity [165]. Additionally, MCT4 silencing shows effectiveness in 
decreasing migration capacity of cancer cells [124], by mechanisms that involve interaction 
of MCT4 with β-integrin [166]. Silencing of MCT1 and MCT4 inhibits cancer cell invasion 
[157]. Moreover, studies with the MCT1 inhibitor α-cyano-4-hydroxycinnamate (CHC) 
showed promising results once it demonstrated capacity for lag tumor growth and increase 
tumor radiosensivity [65], decreasing tumour invasion [165]. Also, lonidamine [163] and 
small interference (siRNA) have been used to inhibit the activity or expression of MCTs, 
respectively, showing relevant effects on tumor [65,163,164]. Also, the relevance of MCTs 
for tumour growth was confirmed by a more specific approach, where combined silencing of 
MCT1, MCT4 and CD147 significantly decreased glycolytic rates and retarded tumour 
growth [167]. Importantly, the use of MCT1 specific inhibitors, already designed by 
AstraZeneca, may also be an effective strategy to block MCT1 activity in cancer [168], 
having a related orally administered compound, AZD3965 (AstraZeneca), currently in Phase 
I/II clinical trials for treating advanced solid tumours [66].  
 
1.6.1. MCT targeting in prostate cancer 
Little is known about the true effects that may result from blocking the function of MCTs 
in prostate cancer. In theory, as well as by experience in other types of cancer, MCT 
targeting may be a promising therapeutic approach against prostate cancer, in general, and 
against the aggressiveness phenotype and angiogenesis in particular. 
An in vivo study from Kim and colleagues, showed that MCT1 activity inhibition using 
CHC did not have a significant effect on tumour volume, although it was associated with 
increased necrotic fraction [169]. 
Since there are yet no sufficient reports about the true relevance of MCTs in the 
development and progression of prostate cancer, it is important to invest in studies 
assessing both the blocking and silencing of MCTs in this type of cancer, in order to reach 
a conclusion about the effectiveness of this therapeutic approach. 
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2.1. Rationale and aims 
Currently, there is a lack of effective therapies against prostate cancer, being the 
existent therapies much invasive for patients. Thus, once prostate cancer is one of the most 
incident cancers worldwide in men, it becomes urgent to perform studies exploring new 
therapies in this type of cancer. 
In this work, we propose the approach of MCTs as targets for a new targeted therapy 
in prostate cancer. As previously mentioned, MCTs play an important role in the 
maintenance of glycolytic metabolism, by exporting lactate by a proton symport mechanism. 
Importantly, a previous study performed by our group [158] showed that MCT1 and the 
chaperone CD147 are downregulated in human prostate cancer tissues. Moreover, the 
same study described the presence of MCT4 in the transition area from normal to tumoral 
tissues, suggesting its role in prostate cancer progression, being the presence of both MCT1 
and MCT4 along with CD147 associated with poor prognosis of patients [158]. 
Thus, laying the described for cases of human prostate cancer where MCTs are 
associated with prostate cancer progression, as well as with poor prognosis of patients, 
becomes relevant bet in the study of the real contribution of MCTs to the survival and 
aggressiveness of prostate cancer in order to assess their potential as a therapeutic target 
in this type of cancer. 
So, the specific aims of this project are: 
1. Characterize the expression of MCTs and chaperones, as well as the expression 
of selected metabolic marker relevant in glycolysis, such as GLUT1, CAIX, HKII, 
LDH, PDK, PDH and HIF-1α. in different prostate cell lines; 
2. Determine the effect of MCT1 and MCT4 downregulation, by siRNA, in prostate 
cancer, by assessment of important parameters in cancer such as cell viability, 
proliferation and migration, using in vitro models of prostate cancer; 
3. Evaluate the contribution of MCTs to prostate tumour growth and angiogenesis by 
performing the downregulation of MCTs in an in vivo model, namely chicken 
chorioallantoic membrane (CAM) model. 
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3.1. Cell Culture 
The in vitro experiments were performed using different prostate cell lines as models, 
all obtained from the American Type Culture Collection (ATCC). 22RV1 (ATCC® CRL-
2505™) cell line is derived from a localized human prostate tumor and DU145 (ATCC® HTB-
81™) is derived from a metastatic prostate tumor on brain, so as to draw conclusions 
according to tumor aggressiveness (localized or metastatic). 
Cell lines were maintained in Roswell Park Memorial Institute-1640 medium (RPMI, 
GIBCO, Invitrogen) supplemented with 10% fetal bovine serum (FBS, Gibco, Invitrogen) and 
1% of antibiotic (penicillin/streptomycin, 10 μg/ml, Gibco, Invitrogen), at 37ºC in a humidified 
atmosphere of 5% CO2. 
 
3.2. Preparation of Cell-Paraffin-Blocks 
For protein characterization and localization, cells were grown in T75 flasks, in RPMI 
with 10% FBS and 5% Penicillin-Streptomycin (Gibco, Invitrogen), until 95% confluence. 
Then, cells were trypsinized and centrifuged at 1200 rpm, for 5 minutes. Cell pellets were 
fixed in formaldehyde 3.7%, overnight and re-centrifuged and then processed in an 
automatic tissue processor (TP1020; Leica), before inclusion into paraffin-blocks (block-
forming unit EG1140H; Leica). 
 
3.3. Immunocytochemistry 
Immunocytochemistry (ICC) for MCT1, MCT4, CD147, CD44, GLUT-1, CAIX, HKII, 
LDH5, PDK, PDH and HIF-1alpha was performed in 4μm cytoblock sections, from the 
previously made cell-paraffin-blocks and staining was analyzed for protein expression, 
distinguishing cytoplasmic from plasma membrane expression. ICC is a technique based on 
the principle of antibody-antigen interaction that allows the detection of target proteins in 
biological tissues, providing a direct method to identifying the subcellular protein distribution. 
The antibody-antigen interaction is visualized using a chromogen, in which the enzyme 
conjugated to the antibody cleaves a substrate to produce a colour precipitate (brown colour) 
at the location of the interest protein. IHC for MCT1, PDK, PDH and HIF-1α was performed 
according with the avidin-biotin-peroxidase principle (R.T.U. Vectastin Elite ABC kit; Vector 
Laboratories). For CD147, CD44, MCT4, GLUT-1, CAIX, LDH and HKII, IHC was performed 
with the Ultravision Detection System Anti-polyvalent, horseradish peroxidase (HRP) (Lab 
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Vision Corporation). Briefly, deparaffinised and rehydrated slides were submitted to 
adequate heat-induced antigen retrieval, for 20 minutes, at 98ºC, followed by endogenous 
peroxidase activity inactivation. After the blocking step of 10 minutes (LabVision kit) or 20 
minutes (Vector kit) slides were incubated with the primary antibody. After, rising in 
phosphate-buffer saline (PBS), slides were incubated with secondary biotinylated antibody, 
for 10 minutes (LabVision kit) or 30 minutes (Vector Kit), and then incubated with streptavidin 
peroxidase for 10 minutes (LabVision kit) or avidin peroxidase for 45 minutes (Vector kit) at 
37ºC. The immune reaction was visualized with 3-3’-Diaminobenzidine (DAB+ Substrate 
System; Dako) as a chromogen. All sections were counterstained with Gill-2 haematoxylin 
and mounted in Entellan®. Each immunoreaction was performed according to the specified 
in the Table I. 
 
Table I. Immunocytochemistry details for each antibody. 
 
Antibody Company Reference Dilution 
Antigen 
retrieval 
Peroxidase 
inactivation 
Positive control 
MCT1 
Santa Cruz 
Biotechnology 
sc-365501 1 :500 
EDTA  
(1mM, pH=8) 
3% H202 in 
methanol, 
30min 
Colon carcinoma 
MCT2 
Santa Cruz 
Biotechnology 
sc-14926 1 :200 
Citrate  
(10mM, pH=6) 
3% H202 in 
methanol, 
10min 
Colon carcinoma 
MCT4 
Santa Cruz 
Biotechnology 
sc-50329 1 :500 
Citrate 
(10mM, pH=6) 
3% H202 in 
methanol, 
10min 
Colon carcinoma 
CD147 
Santa Cruz 
Biotechnology 
sc-71038 1 :400 
EDTA 
(1mM, pH=8) 
3% H202 in 
methanol, 
10min 
Colon carcinoma 
CD44 AbDSerotec MCA2726 1 :1000 
Citrate 
(10mM, pH=6) 
3% H202 in 
methanol, 
10min 
Colon carcinoma 
GLUT-1 Abcam ab15309-500 1 :500 
Citrate 
(10mM, pH=6) 
3% H202 in 
methanol, 
10min 
Colon carcinoma 
CAIX Abcam ab15086 1 :2000 
Citrate 
(10mM, pH=6) 
3% H202 in 
methanol, 
10min 
Stomach 
LDH-5 Abcam ab101562 1 :1000 
EDTA 
(1mM, pH=8) 
3% H202 in 
methanol, 
10min 
Colon 
PDH Abcam ab67592 1 :300 
EDTA 
(1mM, pH=8) 
3% H202 in 
methanol, 
10min 
Stomach 
PDK Abcam ab110025 1 :500 
EDTA 
(1mM, pH=8) 
3% H202 in 
methanol, 
10min 
Stomach 
HKII Abcam ab104836 1 :750 
EDTA 
(1mM, pH=8) 
3% H202 in 
methanol, 
10min 
Colon carcinoma 
HIF-1α BD Bioscience 610958 1 :100 
EDTA 
(1mM, pH=8) 
3% H202 in 
methanol, 
10min 
Glioblastoma 
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3.4. Western blotting 
The Western blot is an analytical technique used to detect specific proteins in sample 
extracts. Gel electrophoresis is used to separate denatured proteins and the proteins are 
transferred into a membrane, being labeled with specific antibodies to target protein(s). Cells 
were grown to 80% confluence, in T25 flasks and then protein samples were prepared by 
collecting the cells in lysis buffer containing 1% Triton-X, 1% NP-40, 0,1 mM EDTA, 50 mM 
Tris pH 7.5, 150 mM NaCl and 1/7 protease inhibitor cocktail, for 15 minutes and then 
centrifuged at 13.000 rpm, 15 minutes, at 4ºC. The supernatant was collected and the 
protein concentrations determined according to the Bio-Rad Dc Protein Assay (500-0113, 
Bio Rad). Aliquots of 20 μl of total protein were separated on 10 % (w/v) polyacrylamide gels 
by SDS-PAGE and transferred into nitrocellulose membranes (Hybond-c Extra, Amersham 
Bioscience) using a wet system. Membranes were blocked with 5% milk, in TBS/TW 0.1% 
Tween for 1 hour at room temperature. After overnight incubation at 4ºC with the primary 
polyclonal antibodies, membranes were washed in TBS/0.1% Tween and incubated with the 
respective secondary antibodies. Signals of the bound antibodies were detected by 
chemiluminescence (Supersignal West Femto kit, Pierce, Thermo Scientific). β-Actin was 
used as the positive control. Table II shows the specifications needed for each antibody.  
 
 
 
 
 
 
 
 
 
 
3.5. Small-interference RNA and Lipofection 
Small interfering RNA (siRNA) is a class of double-stranded RNA molecules, with 20-
25 base pairs in length which can interfere with the expression of specific genes with 
complementary nucleotide sequence and can be introduced into the cells by means 
Table II. Western blotting details for each antibody. 
Antibody Company Reference Dilution Secondary Antibody Species 
MCT1 Santa Cruz Biotechnology sc-365501 1 :500 in 5% milk Anti-Mouse 
MCT2 Santa Cruz Biotechnology sc-14926 1 :200 in 5% milk Anti-Rabbit 
MCT4 Santa Cruz Biotechnology sc-50329 1 :2000 in 5% milk Anti-Rabbit 
CD147 Santa Cruz Biotechnology sc-71038 1 :200 in 5% milk Anti-Mouse 
CD44 AbDSerotec MCA2726 1:500 in 5% milk Anti-Mouse 
GLUT-1 Abcam ab15309-500 1:800 in 5% BSA Anti-Rabbit 
CAIX Abcam ab15086 1:1000 in 5% milk Anti-Rabbit 
LDH-5 Abcam ab101562 1:2000 in 5% milk Anti-Rabbit 
PDH Abcam ab67592 1:300  in 5% milk Anti-Mouse 
PDK Abcam ab110025 1:2000  in 5% milk Anti-Mouse 
HKII Abcam ab104836 1:2000  in 5% milk Anti-Mouse 
HIF-1α BD Bioscience 610958 1:1000  in 5% BSA Anti-Mouse 
β-Actin Santa Cruz Biotechnology sc-1616 1:300 in 5% milk Anti-Goat 
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of Lipofection technique, which uses liposomes, or vesicles, that can easily merge with 
the cell membrane since they are both made of a phospholipid bilayer and release 
compounds into the cell [170,171]. The silencing mixture contained Opti-MEM® (Minimal 
Essential Medium, Gibco), siRNA (Santa Cruz Biotechnologies) for each gene under studied 
and a control (scramble) for each one, and Lipofectamine® RNAi MAX Transfection Reagent 
(Invitrogen), added last, in order to allow the siRNA to be enclosed into the vesicles formed. 
The needed quantities are described in Table 3. After 15 min of incubation, 500 ml of the 
mixture were placed into separate wells, in 6-well plates. Cells growing in T25 flasks were 
trypsinized, resuspended in RPMI with 10% FBS and without antibiotic, since the antibiotic 
could be detrimental to cell survival due to the stress caused by lipofection. The density of 
the cell suspension was determined using the Trypan Blue test, by counting in a Neubauer 
chamber. 22RV1 cells were plated at a density of 500,000 cells per well and DU145 at a 
density of 400,000 cells per well, in a total of 1500 ml per well. The following day, the culture 
medium was changed to RPMI with 10% FBS and 1% antibiotic. After some optimizations, 
it was found that silencing was maximum, in both cell lines, on the 4th day of silencing and 
remains unchanged until the 6th day after silencing. 
 
Table III. Quantities (in µL) of needed reagents for the mixture to silence MCTs in cells by the lipofection technique. 
 
3.6. Cell Viability Assay  
Cell viability was analyzed using the Sulforhodamine B assay (SRB, TOX-6, Sigma-
Aldrich). The SRB assay is a colorimetric assay based on the ability of the dye 
Sulforhodamine B to bind electrostatically and pH dependent to protein basic amino acid 
residues of trichloroacetic acidfixed cells. Under mild acidic conditions it binds to the cells 
and under mild basic conditions it can be extracted from cells and solubilized for 
measurement. An increase and/or decrease in the cell number (total biomass) results in a 
simultaneous change in the amount of dye incorporated by the cells in the culture, which 
indirectly indicates the degree of cytotoxicity caused by the knockdown of MCTs. Cell lines 
were plated into 96-well plates, at a density of 9000 cells per well for 22RV1 and 8000 cells 
for DU145 and allowed to adhere overnight in complete medium. The effect of the 
 Condition Optimem siRNA Lipofectamine 
22RV1 
scramble 500 5 3 
siMCT1 500 5 3 
DU145 
scramble 500 7 3 
siMCT1+4 500 2 (MCT1)+5 (MCT4) 3 
The effect of MCT1 and MCT4 silencing on prostate cancer survival and aggressiveness Simões-Sousa S 
71 
knockdown of MCT1 and MCT4 on cell number (total biomass) was determined at 12 and 
24 hours. After reaching the specific time points, the cell culture medium was aspirated and 
the wells were washed with PBS 1x. Then, 100 μl of cold TCA 10% were added per well and 
the plate was incubated during 1 hour at 4 ºC. Following incubation, the wells were washed 
three times with water and allowed to air dry thoroughly (at least 24 hours). When the wells 
were dried, 50 μl of Sulforhodamine B were added and the plate was incubated for 30 
minutes at room temperature. When the incubation was over, wells were quickly rinsed four 
times with acetic acid 1%, and allowed to dry during 30 minutes until no moisture was visible. 
To finalize the assay, 100 μl of Tris 10 mM were added per well and, in a shaker, the plate 
was allowed to incubate for 5 minutes. The absorbance was read at 490 nm, with a 
background absorbance of 655 nm. The results were analyzed using Graph Pad Software 
version 5.03. 
 
3.7. Cell Proliferation Assay  
The effect of MCTs knockdown on cell proliferation was assessed using the 5-bromo-
2´-deoxyuridine (BrdU) assay which is a precise, fast, and simple colorimetric assay to 
measure cell proliferation, which is based on the measurement of BrdU incorporation during 
DNA synthesis in replicating cells. 22RV1 and DU145 were plated in 96-well culture plates, 
at a cell density of 8000 and 9000 per well, respectively. Cells were allowed to adhere 
overnight. The medium was changed to RPMI medium (without FBS). The plates were 
allowed to incubate for 18 hours at 37 ºC in a humidified atmosphere of 5% CO2 and 5 μl of 
5-bromo-2´-deoxyuridine (BrdU, 400μM, Roche Applied Science) were added per well. Cells 
were re-incubated for an additional 6 hours (total of 24 hours of treatment). Following 
incubation, the labeling medium was removed by suction and 100 μl/well of FixDenat was 
added to the cells. The cells were incubated for 30 minutes at room temperature. The 
FixDenat solution was removed and 100 μl/well of anti-BrdU POD working solution (1:100) 
were added. After 90 minutes incubation, the antibody conjugate was removed and the wells 
were washed five times with 200-300 μl of PBS 1x. Finally, the washing solution was 
removed and 100 μl/well of substrate solution were added. After 5-30 minutes incubation, 
the reactions were stopped using 25 μl of 1M H2SO4 (Sigma) and the absorbance was 
measured in a micro-plate reader (Infinit M200, Tecan) at 450 nm with a reference 
wavelength of 690 nm. 
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3.8. Metabolism assays 
Metabolism of prostate cell lines was assessed by glucose and lactate quantification 
using two colorimetric assays. For that, 22RV1 and DU145 cells were seeded in 48-well 
plates (Nunc, Thermo Scientific), at a density of 500.000 and 400.000 cells per well, 
respectively, and allowed to adhere overnight, in complete medium (RPMI, 10% FBS, 5% 
antibiotics). The medium was changed to RPMI (without FBS) at T0. After 12 and 24 hours, 
100 μl of supernatant were collected from each well and transferred to a 96-well plate (Nunc, 
Thermo Scientific) for glucose (Roche Applied Science) and lactate (Spinreact) 
quantification. 
 
3.8.1. Extracellular Glucose Measurement 
In this colorimetric assay, the enzyme glucose oxidase (GOD) catalyses the oxidation 
of glucose to gluconic acid and hydrogen peroxide (H2O2). The H2O2 is detected by a 
chromogenic oxygen acceptor, phenol, 4-aminophenazone (4-AP) in the presence of 
peroxidase (POD). The intensity of the color formed is proportional to the glucose 
concentration in the sample. 
 
 
 
 
In a 96-well plate, 10 μl of supernatant were diluted in 90 μl PBS 1x (1:10). After that, 
10 μl of the first dilution were diluted in 90 μl of PBS 1x (total dilution 1:100). A calibration 
curve based in a range of glucose solutions with different concentrations was performed. 
Finally, 100 μl of glucose reagent was added to the wells and the plate was incubated at 
room temperature for 20 minutes. The blank was made with 100 μl PBS and 100 μl of 
glucose reagent. Absorbance was read at 490 nm. 
 
3.8.2. Extracellular Lactate Measurement 
 In this colorimetric assay, the enzyme lactate oxidase catalyses the oxidation of 
lactate to pyruvate and hydrogen peroxide (H2O2). The formed pyruvate and hydrogen 
peroxide under the influence of peroxidase (POD), 4-aminophenazone (4-AP) and 4-
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chlorophenol form a red quinone compound. The intensity of the colour formed is 
proportional to the lactate concentration in the sample.  
 
 
 
 
In a 96-well plate, 2 μl of supernatant were added per well. A calibration curve based 
in a range of lactate solutions with different concentrations was performed. After, 200 μl of 
lactate reagent were added to the wells and the plate was incubated for 10 minutes. The 
blank was made only with 200 μl of lactate reagent. Absorbance was read at 490 nm. 
 
3.9. Cell Migration / Wound Healing Assay 
The Scratch Wound Healing Assay is a simple and inexpensive technique used to 
study the effects of a variety of experimental conditions, like gene-knockdown or chemical 
compound treatment, on cell migration. In this assay, a “wound gap” is created by a scratch 
in a cell monolayer, followed by monitoring the “healing” of this gap by cell migration. This 
assay helped us to understand the migratory capacity of the cells after MCTs knockdown 
and it was performed as previously described [154]. The cell lines 22RV1 and DU145 were 
seeded in a six-well culture plate (Nunc, Thermo Scientific), at a density of 600.000 and 
500.000 cells/well. After reaching 95 % of confluence, the cell monolayer was “wounded” by 
scraping it with a 200 μl pipette tip and washed with PBS 1x. Then, cells were covered with 
RPMI medium (without FBS). Specific scratching sites of the wound areas were analyzed 
and photographed at 0 and 24 hours. The relative migration distances were analyzed using 
the software QWound (developed at the ICVS by the biomedical engineering team) and data 
were expressed in % of control migration. 
 
3.10. Chicken Chorioallantoic Membrane (CAM) Assay 
The chicken chorioallantoic membrane (CAM) assay is a quick, technically simple, and 
inexpensive in vivo assay. After tumor development, the blood vessel network can be easily 
accessed, manipulated and observed providing an optimal setting to study the effect of lack 
of proteins, in this case MCTs, in the tumor growth as well as the formation of new blood 
vessels (angiogenesis). The main problem of this technique is consistency of the assays, 
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which implies the use of a large number of eggs. The CAM assay was performed as 
previously described [154,172]. Fertilized chicken eggs (Pinto Bar) were incubated at 37 ºC. 
On day 3 of development, after puncturing the air chamber, a hole in a specific region of the 
eggshell was performed and eggs were sealed with tape and returned to the incubator. On 
the 10th day of development, a plastic ring was placed on the CAM and the different 
conditions of tumor cells in study (22RV1 scramble and siMCT1, DU145 scramble and 
siMCT1+4) were injected inside the ring. The eggs were tapped and returned to the 
incubator. The effect MCT silencing on tumor growth and vascularization was assessed after 
14 days of development. In the 14th day, digital images of the egg were taken in a 
stereomicroscope (Olympus S2 × 16), using a digital camera (Olympus DP71) and, after 
that, the chicken embryos were sacrificed by 10 min incubation at -80 ºC and the CAMs 
were dissected in order to take ex ovo digital images.  
 
3.11. Statistical Analysis 
All graphs and statistical analysis were performed with the Graph Pad Prism 5 
software. The results were expressed as mean ± SEM. Statistical significance between two 
groups was assessed by t-test. P values ≤0.05 were considered statistically significant. 
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4.1. Characterization of expression of MCTs, CD147, CD44 and 
metabolic markers in prostate cancer cell lines 
Assessment of the role of MCTs in prostate cancer was done using two different 
prostate cell lines, with distinct phenotypes. 22RV1 cell line derives from a localized prostate 
cancer, representing therefore a less aggressive cancer, and DU145 cell line, in turn, derives 
from a cerebral metastasis of a prostate tumor, representing a tumor with more aggressive 
phenotype.  
Prostate cancer cell lines were firstly assessed for the expression of different 
metabolic markers, namely HKII, LDH-5, GLUT-1, CAIX, PDH and PDK, as well as for 
MCT1, MCT2, MCT4 and their chaperones CD147 and CD44. This procedure allowed us to 
characterize the expression of relevant proteins on glycolytic metabolism, in order to predict 
if these protein will may play a role on the energetic metabolism of prostate tumor cells. This 
characterization was done by Western blotting for the assessing of expression levels, while 
the cellular localization was assessed by immunocytochemistry.  
Despite Western blotting not showing the cellular localization of proteins, it is a 
sensitive method regarding to protein expression level. As can be seen by Figure 21, MCT1 
is expressed in both cell lines, with less expression in 22RV1 cells in comparison with 
DU145. The expression of MCT2 was only observed in less aggressive cell line, being 
absent in DU145 cells. Importantly, 22RV1 cells do not express MCT4 at all, being this 
protein largely expressed in DU145 cell line.  CD147 was present in both cell lines, although 
with slightly smaller expression in 22RV1, while CD44 was expressed exclusively in DU145.  
 
 
 
 
 
 
 
 
 
 
Figure 21. Western blotting analysis of the expression of MCTs and glycolytic markers in 22RV1 and DU145 cell lines. 
Loading order: 22RV1 / DU145. 
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In what regards to the selected panel of glycolytic markers, GLUT-1, LDH-5 and PDK 
were expressed in both 22RV1 and DU145 cells, with similar levels, however, expression of 
CAIX and PDH was only present in 22RV1 cells, while HKII appears both in 22RV1 and in 
DU145 cells, with a decrease in the second cell line. HIF-1α only showed expression on 
DU145 cells.  
Concerning to cellular localization of the expressed proteins, as shown in the Figure 
22, MCT1 was expressed in both membrane and cytoplasm of 22RV1 cells, while in DU145 
no membrane expression was detected, having only a slight presence in cytoplasm of these 
cells. MCT2 was expressed in 22RV1 cells’ plasma membrane, but not detected in DU145 
cells as seen previously by Western blot results. MCT4 seems to be present in both plasma 
membrane and cytoplasm of DU145 cells, with a slight expression in the cytoplasm of 22RV1 
cells. In what regards to the known chaperones of MCT1 and MCT4, both CD147 and CD44 
were expressed in DU145 cell, exclusively at the plasma membrane. Regarding the 
relationship of MCTs and CD147 or CD44, it can only be seen an association of chaperones 
with MCT4 for DU145 cells, but not in 22RV1 which, in fact, there was no membrane 
expression of MCT4, in contrast with DU145 cells. However, despite no expression of either 
CD147 or CD44 in 22RV1 cells, some membrane expression for MCT1 could be detected.  
 
 
Figure 22. Expression of MCT1, MCT2 and MCT4 in 22RV1 and DU145 cell lines assessed by immunocytochemistry. The 
expression of CD147, chaperone of MCT1 and MCT4 was also assessed. (400x magnification) 
 
Additionally, the expression of a panel of relevant glycolytic markers was assessed in 
order to evaluate the involvement of the glycolytic metabolism in the prostate cell lines under 
study. As can be seen in Figure 23, both cell lines expressed GLUT-1, although membrane 
expression for this marker only appeared in DU145 cells. CAIX, LDH-5, PDH and PDK were 
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expressed in both cell lines, being HKII only expressed in 22RV1 cells and nuclear HIF-1α 
in DU145 cells. Importantly, LDH-5 and HKII expression was higher in 22RV1 than in DU145 
cells, with a cytoplasmic staining pattern. 
 
 
Figure 23. Expression of glycolytic markers in 22RV1 and DU145 cell lines, assessed by immunocytochemistry. (400x 
magnification) 
 
4.2. Effect of MCT downregulation on cellular metabolism of prostate 
cells 
After assessment of the expression of MCTs in 22RV1 and DU145 cells, we performed 
the silencing of the expressed MCTs in each cell line by siRNA. Thus, according to the 
expression results, for 22RV1 cell line we silenced MCT1, whereas for DU145 silenced both 
MCT1 and MCT4, and not each isoform separately, since it has been already observed that 
isoforms can perform a compensatory activity between each other. 
As can be seen in the graphs of Figure 24, after silencing of MCT1, 22RV1 cells 
showed a significant increase in glucose consumption when compared to control, after 12 
hours from the start of the test. On the other hand, DU145 cells decreased its glucose 
consumption at the same time point and, more significantly, after 24 hours from the 
beginning of the test.  
In what regards to the effect of MCTs downregulation on lactate efflux by prostate 
cancer cells, it can be seen a very significant decrease in both cell lines, with much greater 
impact on 22RV1 cell line, with significant differences for both 12 and 24 hours. 
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4.3. Effect of MCTs downregulation on prostate cancer cells survival 
As said before, MCTs has been shown an important role in the resistance to the acidic 
microenvironment of tumors, thus, becomes relevant to investigate how their absence 
affects cancer cell survival. 
In order to study the role of MCTs on tumour cells survival, viability tests were 
performed, using the Sulforhodamine B assay.   
 
Figure 25. Effect of MCT silencing on the percentage of live cell biomass after 12 and 24 hours. Results represent the mean 
± SEM of two independent experiments, each one in triplicates. * p≤0.05, *** p≤0.0001 compared to control (scramble). 
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Figure 24. Effect of MCT silencing on the cellular metabolism behavior of prostate tumor cells, by assessment of glucose 
consumption and lactate production at 12 and 24 hours. The results represent the mean ± SEM of at least three independent 
experiments, each one in triplicate. * p≤0.05, ** p≤0.005, *** p≤0.0001 compared to control (scramble). 
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The response of downregulation in terms of viable prostate cancer cells was measured 
after 12 and 24 hours, for both cell lines. In the graphs of figure 25, can be seen that, 
comparing to controls from both cell lines, MCT1 downregulation in 22RV1 cells leads to a 
significant decrease in viable cellular biomass until 12 hours, being this effect slightly 
reduced from 12 hours onwards, once from here the cells with silenced MCT1 seems to 
recover their ability to grow. In the case of DU145 with downregulated MCT1 and MCT4, 
although the effect on cell viability is less significant than those detected in 22RV1 cell line 
at 12 hours, a continuous effect can be seen on cell viability in comparison to the control, in 
contrast to what happens in 22RV1 cells. 
 
4.4. Effect of silencing of MCTs on proliferation of prostate cancer 
cells 
Tumor cells acquire distinct capabilities in comparison with normal cells, being one of 
them, as referred before, the capability to proliferate indefinitely. Adding to this, 
monocarboxylate transporters are proven to be involved in cell proliferation, since they 
cause a microenvironmental acidity, by exporting a proton along with the lactate molecule 
which, despite giving strength to tumor cells, is harmful for the surround normal cells, 
allowing tumor cells to grow. Thus, the effect of silencing of MCT1/4 on the proliferation of 
prostate cancer cells was analyzed in order to assess the implication of MCTs in the 
proliferation capacity of prostate cells. This analysis was performed by the BrdU assay, by 
measuring BrdU incorporation during DNA synthesis after 24 hours (Figure 26).  
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Figure 26. Effect of MCT silencing on prostate tumor cell proliferation, assessed by BrdU incorporation in DNA of prostate cell 
lines at 24 hours. Results represent the mean ± SEM of two independent experiments, each one in triplicate. * p≤0.05 compared 
to control (scramble). 
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It is possible to observe that silencing of MCT1 in 22RV1 cells promoted a significant 
reduction on cellular proliferation compared to the control. On the other hand, the silencing 
of MCT1+4 in DU145, did not produce any effect in terms of proliferation, comparing to 
control. 
 
4.5. Effect of MCTs downregulation on migration capacity of prostate 
cancer cells 
As it is known, the majority of cancer cells have the ability to migrate through the body, 
from the original organ to others, adjacent or non-adjacent, which contribute to metastasis, 
instilling difficulties in the treatment and increasing mortality rates. Thus, constituting 
migration an important factor when we talk about cancer, we analyzed the effect of the 
silencing of MCTs on the migration capacity of prostate cancer cells. For that, we used the 
scratch-wound healing assay for 22RV1 and DU145 cells with downregulated MCTs and 
assess the effect for 24 and 48 hours. 
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Figure 27. Inhibitory effect of MCT silencing on 22RV1 and DU145 cells migration capacity. Above, representative pictures of 
the migratory capacity of 22RV1 and DU145 cells, both controls and silenced conditions for each cell line. Below, graphs 
representing the respective percentage of cell migration inhibition by MCT silencing for 24 hours. Results represent the mean  
± SEM of at least three independent experiments. * p≤0.05 compared to control (scramble). 
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The results obtained from this assessment (Figure 27), showed that the migration 
capacity of 22RV1 cells was significantly inhibited when MCT1 was downregulated. In 
contrast, DU145 cells continued to migrate, in the same way, even without expression of 
MCT1 and MCT4. 
 
4.6. Effect of MCTs downregulation on in vivo tumor formation 
capacity 
The complexity of a living system cannot be achieved through in vitro studies. In 
cancer research, as in several other research areas, in vitro studies give us a view of the 
effects and mechanisms that are probable, however they are not able to mimic the real  
involvement of the human body and all the constrains underlying it. Then, and before 
proceeding to human clinical trials, it turns necessary to use in vivo models in order to 
confirm the previously achieved in vitro results. In this work, we used de chicken embryo 
chorioallantoic membrane (CAM) as in vivo model for induction of prostate tumors using cell 
lines, in order to assess the effect of MCT silencing in the capacity of prostate cells to give 
rise to tumors, as well as to have a first vision on the recruitment and formation of blood 
vessels into the formed tumor (i.e. angiogenesis).  
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Control conditions (scramble) of Figure 29, effectively show that both 22RV1 and 
DU145 cells have the capability of forming in vivo 3D tumors, despite that the tumors formed 
by the metastasis-derived cell line being smaller. However, only control samples were able 
to form visible tumors in the CAM; in fact, when we look at the conditions with silenced 
MCTs, the growth of tumors to a visible size was strongly inhibited for both cell lines. 
Additionally, silenced conditions of both cell lines seem to provoke some kind of 
inflammatory reaction on the cell injection site of CAM, especially in the condition with 
silenced MCTs in DU145 cells, since we observed in this area, the presence of a liquid milky 
substance, with a distinct consistency from that observed in tumors of control samples. 
In what regards to blood vessel formation or recruiting by formed tumors, it can be 
seen a clear blood vessel formation in the 22RV1 cells-derived tumor, but not so clearly on 
the tumor formed by DU145 cells.  
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General Discussion 
The searching for effective treatments against cancer has constitute an increasing 
research area along the last years, being the “core” of this challenge, the achievement of a 
way to specifically kill cancer cells, while normal cells are spared. The increasing knowledge 
regarding the understanding of tumor biology has greatly contributed to the advancement in 
this area, as it has allowed the identification of several distinct characteristics between 
normal and tumoral cells, which therefore has paved the way for new potential targets which 
may be used in the treatment of this disease.  
The known special capabilities of cancer cells giving rise to tumor, in a general way, 
the potential to grow unreservedly, to resist to mechanisms of cell dead, to evade the 
immune response and, importantly, to reprogram its metabolism allowing it to withstand the 
adversities of the resultant microenvironment, constitute a panel of distinctive features which 
can be used against themselves. The recognition of this last feature of cancers (i.e. 
reprogramming energy metabolism), has led to deeper studies that have led, in turn, to the 
discovery of new putative targets for cancer therapy, including the monocarboxylate 
transporters, important players in the maintenance of the glycolytic metabolism that, along 
with the phenomenon called “Warburg effect”, is a proven characteristic of most tumors 
[24,26]. 
With this study, we tried explore MCTs as targets for a targeted therapy against 
prostate cancer which is, currently, the second most frequently diagnosed cancer of men 
and the fifth most common cancer overall [1]. 
 
5.1. Metastatic prostate cancer is more glycolytic than localized prostate 
cancer 
The Warburg effect, that is the adoption of a glycolytic metabolism by tumoral cells, 
even in normoxia conditions constitutes a widely described event in several types of cancer 
[31]. Associated to this, there is an increase in lactate production and, therefore, an 
upregulation of its main transporters, MCTs, which are already described in many tumor 
types [127,129,130,136,147-153,155,158]. Particularly, in prostate cancer, the information 
about the role of MCTs is still scarce. A study by Hao et al. [151] on human samples of 
prostate cancer described a wide expression of MCT1 and MCT4 in prostate tumors, 
contrasting with another recent study from Pértega-Gomes and colleagues [173], which 
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described an upregulation of MCT2 and MCT4, but not MCT1, when compared to normal 
prostate tissues, being the expression of MCT4, along with CD147, associated with tumoral 
progression to malignant phenotypes and with poor prognosis of patients. In the present 
study, we assessed MCT expression in cell lines, representing less (22RV1) and more 
aggressive (DU145) phenotypes of prostate cancer. The results showed that the metastasis-
derived cell line, DU145, had a higher expression of MCT4, CD147 and CD44 when 
compared to the localized prostate tumor-derived cell line, 22RV1, which has, in turn, higher 
expressions of MCT1 and MCT2. The higher expression of MCT4 and chaperones in DU145 
cells was in fact concordant with the described by Pértega-Gomes, about the correlation of 
MCT4 and CD147 with more aggressive phenotypes of prostate cancer [173]. In addition, 
we support the role of CD147 and CD44 as chaperone for MCT4, since MCT4 was localized 
in plasma membrane in these cells, with co-expression of CD147 and CD44, as it would be 
expected from glycolytic cells. Moreover, consistent with the glycolytic phenotype proposed 
for DU145 cells, along with membrane expression of MCT4, we saw an evident membrane 
expression of GLUT-1, supporting its role in glucose uptake. Moreover, once HIF-1α 
regulates positively a wide panel of proteins in the context of altered metabolism of cancer 
cells, namely GLUT-1 HKII, PDK, PDH, LDH, CAIX and MCT4 [65], it would be expected 
that DU145 cell line had a higher expression of these proteins, since we saw nuclear 
expression of HIF-1α in this cell line. In fact, besides the expression of LDH, PDK and HKII 
which was similar in both cell lines, a relationship between HIF-1α and those proteins can 
be seen in DU145 cells, which shows membrane expression of GLUT-1 and MCT4, involved 
in glucose uptake and lactate efflux, respectively.  
In contrast to DU145, 22RV1 cells do not show any expression of MCT4 and GLUT-1 
expression was cytoplasmic. Importantly, there was a cytoplasmic expression of both MCT1 
and MCT2, in 22RV1 cells, which may be related with the described role of these proteins 
in lactate oxidation complex to maintain the organelle redox status, meaning that their 
cytoplasmic expression could be associated to mitochondria and/or peroxisome 
[111,112,114], consistent with the idea of a more oxidative cell line. In addition, 22RV1 cells 
shows a higher expression of PDH in comparison with DU145 cells, which points once again 
to a more oxidative phenotype, since PDH is responsible for the conversion of pyruvate 
resulting from the glycolytic pathway, into acetyl-CoA, which is directed to mitochondria for 
oxidative phosphorylation [29,30]. This is in line with what was said before about the reason 
for the presence of cytoplasmic MCT1/2 in this cell line.  
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On the other hand, despite with low level, some membrane expression of MCT1 can 
be seen in 22RV1 cells. Taking that into account, although this line seems to be more 
oxidative than glycolytic, it expressed some levels of glycolytic metabolism-associated 
proteins, such as GLUT1, PDK, HKII and LDH so, the lack of MCT4 in these cells may be 
compensated by MCT1 for efflux the lactate produced, once it is an isoform with 
intermediated affinity for the substrate and so, it can perform both the uptake and export of 
lactate [67]. Additionally, since the extracellular acidity is a feature of most cancers, the 
presence of CAIX in 22RV1 cells can also compensate the lack of MCT4 in the role of 
microenvironmental acidifier [58,63]. Moreover, giving the membrane expression of MCT1 
in 22RV1 cells and the lack of membrane CD147 or CD44, it can be hypothesize that some 
other protein, yet undescribed, can be performing the role of chaperone for MCT1. 
In short, from the results of the models used, it appears that the more aggressive 
prostate cancer phenotype is associated with a more glycolytic metabolism, confirming the 
effect of the known metabolic adaptations along the carcinogenesis [31]. 
 
5.2. MCT downregulation is harmful to localized prostate cancer in vitro 
Accordingly with the available information in the literature, MCTs are involved in a 
number of roles in the human body but, importantly, they are upregulated in cancer, which 
is generally associated with increased growth of tumors, as well as aggressiveness features, 
such as high proliferation rates and migration capability between different parts of the body, 
among others [37,38]. In prostate cancer, studies has been performed showing the 
upregulation of MCTs in human samples of prostate cancer [151,158] and, in fact, in this 
study we confirmed the high expression of MCT4 in metastatic (i.e. more aggressive) cells 
originated from prostate, associating metastatic tumor with glycolytic metabolism, while for 
non-metastatic cells (i.e. less aggressive, localized tumor) we saw an association with MCT1 
and MCT2 expression, being these cells less glycolytic.  
Following the rationale that MCTs may be important for survival and aggressive 
behavior of cancer cells, and once they are highly expressed in those cells, we performed a 
series of in vitro assays in order to investigate the contribution of these MCTs to prostate 
cancer survival and features of aggressiveness, performing their silencing by siRNA. It 
would be expected that, facing the lack of MCTs, lactate would be accumulated in cell inner 
space, with prejudice for cell survival and integrity, as well as for the energetic metabolism 
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adopted by these cells (i.e. glycolytic) which, theoretically, would be blocked by a kind of 
negative feedback.  
In a general way, silencing of MCTs had a greater impact on 22RV1 than DU145 cells. 
MCT knockdown led, in both cell lines, to a decrease in lactate production as would be 
expected, since MCTs are the responsible for that task [91]. In DU145 cells, as expected, 
this blocking in lactate efflux consequently led to a significant reduction in glucose 
consumption by these cells, confirming the idea of negative feedback regulation. However, 
and contrasting with the expected, MCTs knockdown led to the increase in glucose 
consumption by 22RV1 cells. There may be some explanations for this increase when we 
silence MCTs, being all of them related with the activation, or upregulation, of some other 
energetic pathway, in face of the blocking of glycolysis, for which glucose has been 
redirected. One hypothesis is that 22RV1 cells, which we showed already to be more 
oxidative than glycolytic, in face of the inability to export lactate, may increase even more 
the oxidative phosphorylation pathway, converting pyruvate to acetyl-CoA instead 
converting it to lactate. On the other hand, another possible explanation is that glucose 
continuing to be consumed and is deviated for the pentose-phosphate pathway, which 
originate, among others, NADPH, that have a role in the prevention of oxidative stress, as 
well as in the de novo lipogenesis, which fatty acids produced can be used subsequently to 
produce energy through fatty acid β-oxidation, an already described prostate cancer-
associated pathway [174,175]. Recently, de Bari and colleagues firstly described the 
occurrence of a D-lactate mitochondrial metabolism in prostate cancer, as a way of energy 
production. This D-lactate can enter in the cell via monocarboxylate transporters, like L-
lactate, but importantly, it can be produced in the cytosol through the methylglyoxal pathway, 
being then oxidized in the inner membrane of mitochondria by D-LDH (D-lactate 
dehydrogenase). Moreover, in the same study, mitochondrial oxidation of D-Lactate proved 
to contribute to both ROS scavenging and fatty acid synthesis, becoming important in the 
maintenance of cell viability and proliferation [176]. Having this in mind, it could be 
reasonable to hypothesize that, with lack of MCTs and functional glycolytic pathway, an 
activation or upregulation of methylglyoxal pathway could be performed. This will allow the 
maintenance of cell viability and redox status, at the same time that the production of fatty 
acids is induced to be used by β-oxidation for energy production.  
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5.3. MCT expression is required for the in vivo prostate tumors growth  
The formation of a tumor in a living complex system, requires much more skills by 
tumor cells than those in a monolayer culture, as in case of the in vitro studies. A living 
system includes an entire environmental involvement, with different types of cells, an 
associated immune system, limitation of nutrients and oxygen that cannot be externally 
controlled, angiogenic capabilities and, importantly, a 3D configuration that can make the 
difference comparing with a 2D in vitro culture. Thus, in vivo studies are essential for the 
real perception of the effects of experiments carried out in research, including in cancer.  
In this work, we performed a series of in vitro studies using prostate cancer cell lines, 
and we demonstrate that the inhibition of the expression of MCTs in these cells has an effect 
on several malignant features of prostate cells, namely on survival, proliferation, migration 
and the adopted energetic metabolism. Therefore, taking into account these results, we 
wanted to make a first approach to study the effectiveness of MCT silencing in the formation 
and growth of prostate tumors in a living system, and for that we performed the tumor 
induction in the CAM.  
A very deep analysis was not necessary to verify that tumor growth was severely 
compromised when the expression of MCTs was inhibited. In fact, in the samples where 
MCTs have been silenced, the tumors did not appear to have formed at all, however, we 
have preliminary results (data not shown) where for the samples, the formation of micro-
tumors was checked and they were only visible under microscopic analysis after processing 
and haematoxylin-eosin staining.  This indicates that the lack of MCTs have the ability to 
inhibit tumor growth but not the formation of tumors. 
Importantly, as previously said, it is described that microenvironmental lactate is 
associated with VEGF production, the major angiogenic factor [59] and, in fact, we observed 
a great blood vessels formation in tumors of untreated cells, with normal MCT levels, and 
so with normal glycolytic rates and lactate export. In addition, there was a more evident 
angiogenesis capacity in 22RV1 cells, which can be due to the characteristic of primary 
tumor of these cells. Since these are cells from a primary tumor, they will have all the 
capabilities to settle and grow in a place, hence the greatest growth in the CAM, comparing 
to the metastatic cells. Thus, 22RV1 cells, through the recruitment of blood vessels can 
capture the nutrients they need to survive, which allow a greater growth. On the other hand, 
with metastatic DU145 cells, although more glycolytic and so greater producer of lactate 
which would have an influence on angiogenesis they may have lost some of their capacity 
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for attach [177-180] so they can travel through the body, and may therefore lose advantage 
in local growth and subsistence. 
Interestingly, in the MCT-silenced samples appear what seems to be an inflammatory 
response, detected by the presence of a substance with a liquid milky appearance, spread 
at the site of cell injection on CAM. This suggestion could gain some strength if we think of 
what was said earlier about T-cell inactivation by lactate. In fact, T-cell activation is 
dependent on high rates of glycolysis and therefore on the rapid efflux of lactate [86], being 
its metabolism and function compromised in the presence of high extracellular 
concentrations of lactate which will exert a negative feedback and block lactate efflux, 
decreasing the immune response against tumor [70]. Having this in mind, the MCT silencing, 
with its consequent decrease in lactate efflux from tumor cells, may have provided an 
opportunity for the intervention of the immune system against tumor cells, contributing also 
to the lack in formation of a substantial tumor in the silenced conditions for MCTs.    
 
 
In summary, with these study we demonstrate that MCTs are expressed in prostate 
tumor cells, in an aggressiveness-dependent way for each isoform. Additionally, using in 
vitro prostate cancer models, we demonstrated the effectiveness of MCT1 and MCT4 
expression inhibition in counteracting various characteristics of aggressiveness of prostate 
tumor cells, as well as undermine the viability of these cells. Moreover, we showed the great 
potential of the inhibition of MCT expression in reducing tumor growth and angiogenesis in 
vivo. Thus, despite further studies still be needed, we showed here that MCTs can be 
powerful targets to consider in the development of new targeted therapies in the treatment 
of prostate cancer. 
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In this work we resorted to cell lines to assess the role of MCTs in prostate cancer, 
along with some metabolic markers known for being associated with glycolysis, and we 
suggested that MCTs have different roles in prostate cancer, depending on the isoforms 
expressed in each type of cells. Moreover, we assessed the effect of the inhibition of MCT 
expression in these cell lines and demonstrated a decrease on cell survival and energetic 
metabolism, as well as on proliferation and migration capacity of less aggressive phenotypes 
of prostate cancer. Importantly, MCT silencing showed in vivo capability of decrease tumor 
growth and angiogenesis. However, although the potential of MCTs as therapeutic targets 
in prostate cancer has been demonstrated, further studies will be needed to achieve the real 
value and the effectiveness of MCTs in this therapeutic approach and to take a step forward 
in its use in humans. 
Firstly, it will be necessary to augment the panel of prostate cell lines in order to 
confirm the results obtained in this work for MCTs and metabolic markers expression as well 
as for the effects of MCT silencing. Importantly, “normal” cell lines of prostate need to be 
included in this work to assess the expression and effects of MCT silencing in normal 
prostate cells, in order to evaluate the specificity of these therapeutic approach for cancer 
cells, sparing normal prostate cells.  
Additionally, once we saw a decrease in cell viability due to MCT silencing, by 
measurement of viable cells biomass in culture, it becomes relevant to perform studies on 
cell death, exploring both apoptosis induction and presence of necrosis, in order to confirm 
the effectiveness of MCT silencing in kill cancer cells and not only in decreasing its 
proliferation.  
Moreover, it could be important to use activity inhibitors of MCTs in order to perform 
the same assessment as which was performed for expression inhibition. It is needed to 
assess the effects of such inhibition, in comparison to the expression inhibition already 
performed, once the approaching of an MCT-targeted therapy in humans could be easier 
using activity inhibitors.  
Additionally, along with MCT inhibition, is important to achieve the inhibition of 
molecular chaperones of MCTs, like CD147 and CD44, trying to increase the potency of the 
treatment. Moreover, new regulators of MCTs need to be explored, both molecular (once 
our expression results suggest the existence of other chaperones, besides CD147 or CD44) 
and epigenetic, which stay poorly explored.  
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No less important, since hypoxia is a widely observed condition in tumors and it is 
known its regulation on MCTs and other glycolytic proteins, it could be interesting to perform 
our studies under hypoxia conditions.  
Importantly, we proposed that, due to the inhibition of MCTs and consequent blocking 
on lactate efflux, cancer cells may activate or enhance other pathways to produce the energy 
they need. Thus, to check this possibility and identify these putative pathways, it could be 
necessary to evaluate the expression of specific proteins of the proposed pathways in 
prostate cell lines, comparing whether there is overexpression in the tumor cells compared 
to normal cells.  
Finally, after all these assessments, a more complex in vivo model need to be used, 
such as a mouse model, to ascertain all effects in an organism closest to our true purpose 
of treatment: the human prostate cancer. 
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